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Many individuals with diabetes use medications or exercise to control blood 
glucose concentrations, which can lead to episodes of hypoglycemia.  Although chronic 
hyperglycemia leads to many diabetic complications, hypoglycemia is an acute threat to 
the health of individuals, and can lead to myocardial ischemia and arrhythmias, as well as 
increasing inflammation, oxidative stress, and thrombotic and fibrinolytic processes.  
Either antecedent exercise or antecedent hypoglycemia lead to a blunted counter-
regulatory response to a subsequent hypoglycemia episode.  Acute exercise has been 
shown to increase monocarboxylate transport proteins (MCTs) in the ventromedial 
hypothalamus (VMH) of the brain, which is involved in regulating the counter-regulatory 
response to restore euglycemia.  The MCTs shuttle lactate in and out of cells, however 
when is lactate infused into the VMH has been shown to interfere with the counter-
regulatory response.  Additionally, antecedent recurrent hypoglycemia has been shown to 
increase lactate transport in the brain. Therefore, the current studies investigated what 
effect exercise training or recurrent antecedent hypoglycemia had on MCT proteins in the 
VMH.  Adult male Sprague-Dawley rats were used for both studies, randomized to 
receive either 6-7 weeks of aerobic training, sedentary behavior, 3 days of insulin 
induced hypoglycemia, or 3 days of saline injection.  The increases in cytochrome c 
oxidase activity among the aerobically trained group showed that training adaptations 
occurred, however, there were no significant differences in MCT proteins within the 
VMH between the trained versus sedentary rats.  While each of the 3 days of 
hypoglycemia or saline injection showed differences in 30 minute post-injection glucose 
concentrations, no significant differences in MCTs were observed in the VMH between 
the 2 groups on day 4. 
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CHAPTER I 
 
INTRODUCTION 
 
 
Specific Aims 
 The regulation of blood glucose concentrations is required for the maintenance of 
life and for the overall health of an individual. The ability of the brain to sense the level 
of glucose within the body is paramount to survival. Glucose sensing neurons are found 
throughout the brain, including in the hindbrain and hypothalamus, specifically the 
ventromedial hypothalamus (VMH).  Blood glucose levels above (5.5 mmol/l) or below 
(3.9 mmol/l) the normal range (3.9 – 5.5 mmol/l), initiates a plethora of responses that 
when functioning properly, result in the re-establishment of homeostasis in blood glucose 
concentrations. While blood glucose concentrations fluctuate throughout the day (~3 – 10 
mmol/l), the ability of the body to respond to these fluctuations and normalize glucose 
concentrations is considered a fundamental physiological process. 
The hallmark of diabetes mellitus, either type 1 (T1D) or type 2 (T2D), is the 
inability to maintain blood glucose in the normal healthy range. Over the past 60 years, 
the number of individuals with diagnosed diabetes in the United States has risen from 1.5 
million to about 21 million people, however the number, including those undiagnosed, 
may be as high as 29.1 million 1,2. Euglycemia is the goal of many diabetic treatments, 
however addressing the rises and falls in glucose throughout the day can be difficult.  
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Exercise is commonly recommended for individuals with diabetes (particularly 
T2D) to help manage hyperglycemia.  However, when exercise is combined with 
medications that help lower blood glucose, it can lead to hypoglycemia, a more 
immediate medical risk.  In addition, many individuals with both T1D and T2D use 
exogenous insulin to regulate their blood glucose.  Insulin, while effective at reducing 
blood glucose concentrations, must be carefully dosed to avoid hypoglycemia.  
Hyperglycemia results in increased vascular dysfunction which contributes to 
retinopathy, neuropathy, and nephropathy often observed in diabetic patients, but it also 
poses long term health risks that may lead to increased risk of cardiovascular disease and 
cancer 3-10.   These adverse long-term health consequences of hyperglycemia are the 
impetus for recommendations related to stringent blood glucose control within diabetic 
individuals by way of lifestyle modifications (exercise and/or diet), various oral 
medications (i.e. sulphonylureas or glucophage) or with exogenous insulin.  
Unfortunately, intensive treatment focused on avoidance of hyperglycemia, particularly 
with insulin and sulphonylureas often leads to increased rates of hypoglycemic 
events11,12. Hypoglycemia is a more urgent, acute threat to the health of individuals with 
diabetes.  Hypoglycemic episodes can lead to myocardial ischemia and arrhythmias, as 
well as increasing inflammation, oxidative stress, and thrombotic and fibrinolytic 
processes 11,12.  Therefore, while long-term regulation of hyperglycemia is important, 
recurring incidents of hypoglycemia can pose a more immediate health risk. 
The dangers of hypoglycemia are compounded by the effect that an antecedent 
episode of hypoglycemia can have on a subsequent occurrence.  It has been shown that 
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individuals who are exposed to repeated bouts of hypoglycemia have a blunted counter-
regulatory response to restore euglycemia13.  This cycle of hypoglycemia leading to 
inhibited responses to subsequent hypoglycemia, as well as reduced awareness of 
hypoglycemia, is often called hypoglycemia associated autonomic failure (HAAF). The 
prevalence of autonomic failure among individuals with diabetes has been estimated 
around 25% of insulin treated individuals with diabetes14.  However, studies that examine 
standard treatment compared to more intense treatment (earlier and/or greater insulin and 
oral anti-hyperglycemic medications) of diabetes show that more intense treatment often 
leads to increased risk of hypoglycemia, which may lead to HAAF 11. The long-term 
consequences appear to be a depressed counter-regulatory response to hypoglycemia and 
a decreased sensation of hypoglycemic symptoms.  This puts individuals with insulin 
dependent diabetes mellitus (IDDM) at an even greater risk when they are trying to 
maintain tight control over their blood glucose concentrations, regardless of whether they 
originally developed T1D or T2D 15,16. 
Interestingly, the HAAF response to hypoglycemia has also been observed when 
an incident of hypoglycemia follows an exercise session 17-19.  The blunted counter-
regulatory response observed in autonomic failure has also been observed up to 24 hours 
after acute exercise.  Although those who have an antecedent exercise induced HAAF 
response and those who have antecedent hypoglycemia induced HAAF response display 
common symptoms, it is unclear if the underlying mechanism in the HAAF response 
after antecedent exercise is the same as the mechanisms resulting from antecedent 
recurrent insulin induced hypoglycemia.  Recent studies have shown that there may also 
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be exercise-induced adaptations in the brain area associated with glucose sensing 20,21.  A 
recent study by Takimoto et al. showed that a single bout of exercise in rats was 
sufficient to increase monocarboxylate transport proteins (MCTs) in several brain areas, 
including the hypothalamus.  This is consistent with observations of acute MCT up-
regulation in rat muscle after exercise 22.  These MCTs transport lactate (as well as other 
monocarboxylates) into, out of, or between cells within the brain and other tissues, and 
may be related to changes in lactate concentrations in the ventromedial hypothalamus, a 
region known to be involved with regulation of blood glucose concentrations.  Other 
studies have shown that antecedent recurrent hypoglycemia can lead to increased lactate 
transport in the brain 23.  While it is unknown if these two adaptations have similar 
mechanisms, microdialysis infusion of lactate has been shown to suppress the counter-
regulatory response to insulin induced hypoglycemia, similar to what is seen with HAAF 
24.  This has also been shown with more physiological infusion of lactate into the VMH 
25. In either case, there is decreased sympathetic output, and reduced glucagon and 
catecholamines, despite hypoglycemia 24,25.  Additionally, MCT inhibition (in the 
ventromedial hypothalamus (VMH)) was able to rescue the counter-regulatory response, 
suggesting that lactate may play some role in HAAF 24. 
Therefore, the overall objective of the current study was to investigate what effect 
exercise training or recurrent hypoglycemia has on MCT protein content  within the 
VMH .  Our approach will be to compare the MCTs in; 1) exercise trained rats or 
sedentary rats and 2) rats exposed to antecedent recurrent hypoglycemia or euglycemia.  
Our central hypothesis is that aerobic training as well as recurrent hypoglycemia will 
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increase MCT proteins within the VMHs of trained or recurrently hypoglycemic animals.  
Our rationale for investigating the changes in MCTs is to: 1) attempt to find if this is part 
of a unifying mechanism for antecedent exercise and antecedent recurrent hypoglycemia 
induced HAAF, 2) increase information related to two common treatments for individuals 
with diabetes, and 3) identify potential targets for management of HAAF to allow for 
tight control of blood glucose concentrations in individuals with IDDM. 
Specific Aim 1) Determine if there is a cumulative effect of exercise training on 
MCT protein content in the VMH by comparing 6-7 weeks of exercise training to 
sedentary rats (part of another ongoing study). 
Hypothesis 1; We hypothesize that the amount of MCT2 and MCT4 will be 
greater in rats trained 6-7 weeks compared to sedentary rats. 
Rationale; studies have shown that, in addition to acute treadmill running, 3 
weeks of aerobic training on a treadmill increased MCT content in skeletal muscle 26,27.  
In addition, treadmill running has been shown to increase MCTs in many brain areas 20,21. 
Specific Aim 2a) Determine if 3 days of insulin induced hypoglycemia leads to 
increases in MCT 1, 2, or 4 in the ventromedial hypothalamus compared to control rats.   
Hypothesis 2a; It was expected that elevated levels of MCT 2 and 4 protein in the 
VMH would occur to recurrently hypoglycemic rats to a greater extend compared to the 
control rats. 
Rationale; MCTs have been reported to be approximately doubled in diabetic rats 
which also show signs of HAAF compared to control rats 20.  We also expected this 
increase because 1) lactate can be used to sustain neurons under glucoprivic conditions, 
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2) lactate has been shown to blunt the counter-regulatory response when injected, and 3) 
because antecedent recurrent hypoglycemia has been shown to lead to increased lactate 
transport in the brain as well as HAAF 23,24,28.  Therefore, we expect that the lactate 
transport proteins will increase in content to facilitate increased demand for lactate 
shuttling, and will be associated with HAAF. 
Specific Aim 2b) Confirm a reduced counter-regulatory response to antecedent 
recurrent insulin induced hypoglycemia among the treated rats compared to control rats.   
Hypothesis 2b; It was hypothesized that the recurrently hypoglycemic rats will 
have an impaired counter-regulatory response compared to control rats. 
Rationale; It was expected that recurrently hypoglycemic rats will have depressed 
epinephrine, and possibly glucagon response to insulin induced hypoglycemia compared 
with the control rats which has already been confirmed by several studies 23,29,30. 
Significance 
While rates of diabetes are increasing in the United States and globally, our 
current methods of treatment are not sufficient to reverse or even prevent the progression 
of the disease and its associated morbidities 11.  This is in part due to the inability to 
consistently reduce blood glucose concentrations to healthy levels without fear of 
inducing hypoglycemia.  While T1D and T2D develop along fundamentally different 
pathophysiological pathways, they share several key issues, including the inability to 
aggressively manage blood glucose concentrations for fear of inducing potentially fatal 
hypoglycemic events.  In both diabetic conditions, exercise and anti-hyperglycemic 
medications are used to manage blood glucose; however both treatments, under certain 
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circumstances, lead to hypoglycemia.  In addition, they both may lead to subsequent 
impaired counter-regulatory response to hypoglycemia.  This can become a vicious cycle, 
avoidable only by applying a less aggressive treatment paradigm.  This study is 
significant because it ties together multiple independent areas of research pertaining to 
hypoglycemia, hypoglycemia associated autonomic failure (HAAF), and brain 
metabolism in an attempt to disentangle the underlying mechanisms relating to these two 
common diabetes therapies. 
This research fills a gap in the current literature because it examines MCT protein 
content changes specifically within the VMH to both antecedent exercise and 
hypoglycemia.  Although antecedent exercise and antecedent hypoglycemia may share 
characteristic depression of the counter-regulatory response to subsequent hypoglycemia, 
previous research has failed to recognize the potential common mechanisms and the 
research areas have remained independent.  We will compare changes in MCT protein 
content in the VMH, which may partially moderate dysfunction in the counter-regulatory 
response.  This has not been compared between antecedent exercise and hypoglycemia, 
and to our knowledge has not been examined at all in the recurrent hypoglycemia 
literature.  While both recurrent hypoglycemia and antecedent exercise have been shown 
to lead to impairment of the counter-regulatory response, it is unknown whether the 
changes seen in the MCTs in the VMH are the same.  Therefore as a starting point, we 
may be able to reveal a convergence point through which two different diabetes 
treatments affect subsequent autonomic failure/dysfunction.  This may lead to future 
studies to develop strategies to prevent this dysfunction.  If the risk of autonomic 
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failure/dysfunction were minimized or removed, individuals with diabetes could be 
treated more aggressively, with the ultimate goal to slow the progression of their disease 
and reduce the risk of co-morbidities by more tightly controlling blood glucose 
concentrations without fear of hypoglycemia and HAAF.  
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CHAPTER II 
 
REVIEW OF LITERATURE 
 
 
Overview 
This review of the relevant literature will focus on several research areas related 
to the maintenance of blood glucose in healthy individuals compared to those with 
diabetes, including the normal mechanisms of blood glucose management, the counter-
regulatory mechanisms used to respond to hypoglycemia, mechanisms within the central 
nervous system which help monitor glucose levels, response to changes in glucose and 
consideration of ways in which these mechanisms can be disrupted, including exercise 
and hypoglycemia.  A detailed discussion of the astrocyte to neuron lactate shuttle 
(ANLS) hypothesis, and the lactate shuttling proteins (MCTs) will be included.  Finally, 
the effects of exercise or hypoglycemia on MCTs will be discussed in both skeletal 
muscles as well as in brain.  This review attempts to join together research from two 
separate areas; while both antecedent exercise and antecedent hypoglycemia have been 
examined, the former area focuses on the hormonal response systemically and the latter 
focuses on the changes in the CNS.  In this review both will be discussed in an attempt to 
show that these different perturbations may be leading to similar changes both 
hormonally and within the brain. 
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Regulation of Blood Glucose Concentration  
In healthy individuals blood glucose concentration is maintained within healthy 
parameters by several systems.  Two very important organs involved in the regulation of 
blood glucose are the pancreas and the liver.  Pancreatic islets of Langerhans are clusters 
of endocrine cells that secrete different hormones depending upon the metabolic 
condition of the body, as well as in response to neural stimulation.  These clusters of cells 
include beta-cells, alpha-cells, delta-cells, pp cells, and epsilon-cells.  Of these, alpha and 
beta cells account for the majority of cells within the pancreatic islets.  The liver has the 
ability to not only store glucose as glycogen, but to release this glucose into the systemic 
circulation if blood glucose concentrations dip.  These two organs work in concert, along 
with the CNS, to maintain circulating blood glucose concentrations. 
Post-prandial Regulation of Glucose Concentration; After a meal is consumed, 
blood glucose concentrations are high, and need to be brought back to the normal 
physiologic range.  The pancreatic beta-cells are the cells responsible for regulating blood 
glucose post-prandially, when blood glucose concentrations are high.  Pancreatic beta-
cells express both GLUT 1 and GLUT 3 glucose transport proteins 31.  These proteins 
allow blood glucose to enter the beta-cells where it can be used to produce ATP via 
aerobic glycolysis.  Glucose that enters the cell must be phosphorylated before it can 
enter glycolysis.  Pancreatic beta-cells express glucokinase (hexokinase IV), rather than 
hexokinase I and hexokinase II, which have lower kms for glucose by comparison 32,33.  
This allows glucose to move into the cell easily, but limits movement into glycolysis at a 
high rate unless glucose concentration increases 32,33.  As more ATP is produced, the 
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ATP:AMP ratio is altered and ATP sensitive potassium channels (KATP) are stimulated to 
close, preventing potassium export from the cell.  This results in a rise in the local 
membrane potential, which stimulates voltage gated calcium channels to open and allows 
calcium into the cell.  The influx of calcium stimulates insulin-containing vesicles to 
translocate to the cell surface and release their contents into circulation.  This chain of 
events leads to increases in blood insulin concentration after a meal is consumed.   
Insulin has many actions throughout the body, although the most well-known is 
its role in regulating blood glucose (Figure 1).  Insulin exerts its glucose regulatory 
effects in skeletal muscle, liver, pancreas, and adipose.  In the post-prandial state, insulin 
binds to its receptor located on the cell membrane of a tissue (ie. skeletal muscle), to 
enable the tissue to take glucose from the circulation.  When bound to the receptor in 
skeletal muscle, insulin stimulates the insulin receptor substrate (IRS) to phosphorylate 
phosphatidylinositol 3 kinase (PI3K), which converts phosphatidylinositol 2 phosphate 
(PIP2) to phosphatidylinositol 3 phosphate (PIP3) so that phosphoinositide-dependent 
kinase 1 (PDK) can dock on the intracellular portion of the membrane.  PDK then 
interacts with protein kinase B (Akt), leading to inhibition of the Akt substrate of 160kDa 
(AS160, also known as TBC1D4).  This pathway results in the translocation of 
intracellular GLUT 4 vesicles to the cell surface, increasing GLUT 4 protein at the cell 
membrane, and ultimately, increasing the movement of glucose down its concentration 
gradient in to the cell.  While liver and adipose may also take up glucose, skeletal muscle 
is the primary “sink” for glucose in the post-prandial state. 
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The other major tissue where insulin exerts its effects is the liver.  When insulin 
binds to its receptor in the liver, it stimulates the synthesis of glycogen.  The insulin 
signaling pathway in hepatocytes is similar to that in skeletal muscle.  However, the 
primary action from Akt is not on TBC1D4, but on glycogen synthase kinase (GSK).  
Once GSK is phosphorylated, it is in the inhibited form and decreases the rate of 
phosphorylating glycogen, thus allowing glycogen synthase to become active.  Glycogen 
synthase promotes the formation of glycogen, the primary storage form of carbohydrate.  
Glycogen will remain stored in the hepatocytes until there is a need to increase blood 
glucose concentrations in the body, such as during a fast and/or with exercise, to maintain 
blood glucose concentrations. 
Adipose tissue also responds to insulin stimulation, leading to glucose uptake and 
inhibition of lipolysis 34-36.  However, adipose tissue signals also plays a role in the 
regulation of insulin sensitivity, and the control of chronic blood glucose concentrations 
34.  Adipose tissue, as well as the associated M1 macrophages, can secrete many different 
adipokines which influence metabolism and insulin signaling 34.  Certain adipokines may 
lead to a pro-inflammatory state and interfere directly or indirectly with insulin signaling 
in other tissues 34,35.  The chronic increase in TNF-α, IL-6, resistin, and leptin seen with 
obesity (often preceding T2D) can lead to serine phosphorylation of IRS1/2, decreased 
mRNA for adiponectin, upregulation of SOCS3, and activation of JNK and IKKβ 
signaling pathways 34,35.  All of these changes can lead to a reduced sensitivity to insulin 
signaling34,37.  Regardless of adipokines or body mass, increased lipolysis can lead to 
reduced ability of insulin to properly reduce blood glucose concentrations 36.  This may 
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be related to the proportion of glucose to fat being used for oxidation, or potentially the 
buildup of intramyocellular or intrahepatic lipids 34,36,38,39.  However, because adipose 
tissue and adiposity affect the regulation of blood glucose concentrations over long 
periods of time, rather than in response to feeding or fasting, it will not be discussed 
further.  Although it should be noted that body mass and adiposity do affect the ability of 
other systems to regulate blood glucose concentrations when interpreting data. 
 
 
 
Figure 2.1. The Overall Regulation and Maintenance of  
 
Systemic Blood  Glucose Concentrations in Healthy Individuals40. 
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Maintenance of Glucose Concentration During a Fast; During fasting conditions, 
blood glucose must be maintained within the normal physiologic range from stored 
substrates within the body because no new glucose is entering circulation from the gut. 
The pancreatic alpha-cells are the cells primarily responsible for regulating blood glucose 
concentrations during fasting conditions.  When blood glucose begins to decline during a 
fast, insulin levels also begin to decline while beta-endorphin levels rise 41,42.  The 
reduced insulin relieves the inhibition of glucagon release from alpha-cells, while 
increased beta-endorphins stimulate glucagon release 13,43,44.  The primary location where 
glucagon exerts its effects is the liver.  When glucagon binds to its receptor in 
hepatocytes, it activates adenylate cyclase to produce cyclic AMP (cAMP), which 
activates protein kinase A (PKA). The activation of PKA converts glycogen 
phosphorylase B to phosphorylase A, as well as activating phosphoenolpyruvate 
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pc) transcription.  The 
conversion of glycogen phosphorylase B to A increases its activity.  Glycogen 
phosphorylase cleaves glycosidic 1,4 bonds removing glucose 1 phosphate from 
glycogen molecules.  The glucose 1 phosphate can then be converted to glucose-6-
phosphate by phosphoglucomutase.  In the liver, glucose-6-phosphate can then be 
dephosphorylated by glucose-6-phosphatase, and the free glucose can leave the 
hepatocyte down its concentration gradient.  This is the primary means of maintaining 
blood glucose during relatively short fasts.   
In persistent fasting states, liver glycogen is depleted, so blood glucose 
concentrations are maintained by the production of glucose from non-carbohydrate 
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sources via gluconeogenesis.  This requires the up-regulation of the gluconeogenic 
enzymes within the liver.  PKA, besides its effect on glycogen phosphorylase, activates 
CREB and inhibits salt-induced kinases (SIKs).  The SIKs then release their inhibition of 
CRTC2 (CREB-regulated transcription coactivator 2).  CREB and CRTC2 form a dimer 
and translocate to the nucleus where they act as a transcription factor and bind to 
hormone response elements for gluconeogenic genes.  In addition, the reduced insulin 
concentration (and therefore reduced Akt activation), leads to a reduced inhibition of 
forkhead box protein O1 (FOXO1), which also stimulates gluconeogenic gene 
transcription.  The increase in gluconeogenic enzymes allows the liver to produce glucose 
from sources other than glycogen, primarily pyruvate produced from oxaloacetate or 
alanine.  
Maintenance of Glucose Concentration During Exercise; Another common 
disruption in blood glucose homeostasis occurs when individuals exercise or perform 
physical activity 45,46.  Due to increased energy needs within active tissues, blood glucose 
needs to be maintained to prevent hypoglycemia.  As an individual begins to exercise, 
there is a withdrawal of parasympathetic signaling which can lead to reduced insulin 
secretion, while increases in sympathetic signaling begin to increase circulating glucagon, 
epinephrine, and norepinephrine 45,47-49.  These hormones promote the same signaling 
cascades discussed in the section on fasting glucose control as well as inhibiting insulin 
release.  This promotes the release of glucose from the liver as well as mobilization of 
non-esterified fatty acids from adipose to fuel working muscles 45,47-49.   
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The magnitude of the effect of physical activity is proportional to the intensity 
and duration of the activity.  The signals can adjust as exercise intensity and duration 
change, but throughout, blood glucose concentrations are being maintained.  Although it 
is not common for exercise to produce hypoglycemia in healthy individuals, mobilization 
of glucose within the body must be adequate to match the rate of glucose uptake and use 
by skeletal muscles.  The systems compensating for perturbations in glucose homeostasis 
during exercise are similar to those seen during fasting or hypoglycemia, and are 
therefore potentially therapeutic or problematic for individuals with DM depending on 
how exercise is approached. 
Because the maintenance of blood glucose concentration is so important to health, 
these processes are tightly regulated.  Each signaling pathway is either activated or 
inhibited by many signals, including signals from the CNS.  While insulin alone accounts 
for most regulation during the fed state, there are a multitude of factors such as glucagon, 
norepinephrine, beta-endorphins, and epinephrine, which activate the counter-regulatory 
response to low blood glucose concentrations.   
Maintaining Blood Glucose in Diabetes; Compared to healthy individuals, 
diabetic individuals have difficulty maintaining their blood glucose concentration. 
Diabetes mellitus (DM) is the most notable disease in which the primary symptomology 
is a lack of control of blood glucose concentration. There are generally two different 
forms of DM, which have different root causes, but eventually converge upon a common 
condition. T2D is caused by the progressive loss of responsiveness of body tissues to the 
effects of insulin.  This loss of tissue sensitivity results in progressive hyperinsulinemia 
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and the eventual deterioration of insulin production by the pancreatic β cells, a process 
termed ‘beta-cell exhaustion’.  T1D is caused by an autoimmune response which leads to 
the loss of pancreatic β cells.  Because both forms of DM lead to the loss of pancreatic β 
cells, individuals with either condition may eventually use exogenous insulin to help 
maintain blood glucose concentration.  At that point, these can both be considered IDDM.  
Regardless of the underlying cause of DM, both types have problems with the 
management of blood glucose concentration, which can lead to further health 
complications. 
In both types of diabetes, the effectiveness of insulin is eventually decreased and 
the ability to produce adequate endogenous insulin is compromised.  This leads to an 
inability to lower blood glucose concentration in the post-prandial state.  This is usually 
referred to as impaired glucose tolerance, and leads to post-prandial glucose elevations 
that are greater and longer in duration compared to healthy individuals.  In addition, the 
liver can become dysfunctional and increase hepatic glucose output when it is 
unnecessary50.  This can lead to elevations in fasting glucose concentration, and is 
referred to as impaired fasting glucose.  Because of insulin’s effect on both liver and 
skeletal muscle, exogenous insulin can transiently help to correct both of these 
dysfunctions in individuals with diabetes.  However, skeletal muscle can be stimulated to 
take glucose from circulation independent of insulin signaling under certain conditions, 
such as with exercise.  
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Exercise and Glucose Control; Exercise and physical activity have both been 
shown to help reduce fasting and post-prandial blood glucose concentration in T1D, T2D, 
and non-diabetic individuals 12,15,51-53.  Skeletal muscle contraction enhances glucose 
uptake through an insulin-independent mechanism, thus, the aforementioned beneficial 
effects of exercise and/or physical activity are reliant on this fundamental property related 
to skeletal muscle 54.  Interestingly, the effect of insulin and exercise on glucose uptake in 
skeletal muscle is synergistic rather than just additive 55,56.  In addition, exercise 
sensitizes the body to insulin, leading to increased potency of insulin post-exercise 54-56.  
It has been shown that as little as 7 days of exercise training is sufficient to improve the 
post-prandial glucose regulation in individuals with T2D 52.  Indeed, even in individuals 
with T2D, a single bout of exercise can improve the regulation of post-prandial glucose 
concentration for that day 51.  However, these improvements are lost within a short time, 
usually 24-48 hrs. 
The ability of muscle contractions to increase glucose uptake and enhance insulin 
sensitivity is a double-edged sword for individuals who rely on exogenous insulin to 
control blood glucose concentration. If carbohydrates are not properly balanced with 
insulin dose and physical activity, these individuals can become hypoglycemic post-
exercise 12,15,57,58, and without intervention, it can lead to death in extreme cases.  
Therefore, individuals with diabetes are cautioned to error on the side of maintaining 
higher rather than lower glucose concentrations when treating with insulin, but this limits 
their ability to tightly regulate their blood glucose concentration.   
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Recurrent Hypoglycemia and HAAF 
Counter-Regulatory Response to Hypoglycemia and Autonomic Failure; 
Hypoglycemia is not normally a problem for healthy individuals.  This is because 
initially, as blood glucose concentrations fall, insulin secretion decreases.  This relieves 
the inhibition of insulin on α cells allowing glucagon to rise.  The decrease in insulin 
reduces the uptake of glucose by skeletal muscle and adipose tissue.  The withdrawal of 
insulin also disinhibits the release of glucose from the liver, while glucagon enhances 
both glycolysis and gluconeogenesis in the liver leading to enhanced hepatic glucose 
output.  If these actions do not produce sufficient increases in blood glucose 
concentration, catecholamines (stimulated by the CNS), will further inhibit insulin’s 
effect on the liver, enhance glucagon secretion, and reduce glucose utilization by skeletal 
muscle as seen in Figure 2.  This is the normal counter-regulatory response to 
hypoglycemia and exercise.  However, individuals with DM who routinely become 
hypoglycemic show a reduced responsiveness of this counter-regulatory response to 
subsequent hypoglycemia or exercise 59,60.  Unlike the underlying dysfunction within 
peripheral tissue that results in exacerbated post-prandial or fasting hyperglycemia, the 
dysfunction in the response to hypoglycemia seems to originate from the CNS.  This 
common occurrence in individuals with IDDM has been termed hypoglycemia associated 
autonomic failure (HAAF) 12,13,61.  This central dysfunction results in a highly 
problematic situation for these patients, because they have a blunted response to low 
glucose and reduced awareness of hypoglycemia, but have to use some treatment to avoid 
hyperglycemia. 
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Figure 2.2.  Interaction of the CNS with Peripheral Organs During  
 
a Counter-Regulatory Response to Hypoglycemia 44. 
 
 
Antecedent Hypoglycemia and the Counter-Regulatory Response; One of the 
most common ways individuals with DM can control high blood glucose concentrations, 
either post-prandially, or fasting, is through the use of exogenous insulin injections 
16,50,62,63.  Unfortunately, attempting to tightly control blood glucose concentrations 
though aggressive pharmacological treatment can result in an increase in the incidence of 
hypoglycemia 64,65.  After an individual has had an episode of hypoglycemia, they are 
more susceptible to subsequent hypoglycemia, because there is a loss of the counter-
↑SNS ↓PNS
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regulatory response to hypoglycemia 59.  Interestingly, this effect is seen in individuals 
with DM as well as healthy individuals 15,59,61,66.  While it is unknown what the exact 
mechanisms are, they seem to be related to changes that occur within the hypothalamus 
13,44,59,67,68.  This effect has been extensively studied in both diabetic and healthy 
populations. 
A study by Boyle et al. (1994) used a progressive stepped hypoglycemic clamp in 
healthy humans for 4 consecutive days and measured the counter-regulatory response on 
days 1 and 4 59.  This study showed that by day 4, there were reduced levels of 
norepinephrine, epinephrine, glucagon, as well as autonomic symptoms of hypoglycemia 
59.  Another study by Davis et al (1997) used only one day of antecedent hypoglycemia, 
but divided their healthy participants into groups receiving different depths (3.9, 3.3, or 
2.9mmol/l) of hypoglycemia on day 1 66.  The second day, all participants received the 
same degree of hypoglycemia, and their counter-regulatory responses were measured 66.  
Although all of the participants had the same degree of hypoglycemia and insulin 
concentrations on day 2, the lower the previous day’s hypoglycemia, the lower the 
concentrations of epinephrine, norepinephrine, and glucagon 66.  Davis et al (2000) 
followed this study with another examining how the duration of antecedent hypoglycemia 
affects the counter-regulatory response 69.  Subjects were randomly selected to receive 
antecedent euglycemia or hypoglycemic clamp, allowing blood glucose to decline to 
2.9mmol/l over 30 minutes, and then have euglycemia restored after 5 minutes, 30 
minutes, or 90 minutes 69.  All participants remained on the clamp for a total duration of 2 
hours 69.  The next day, all participants were given a hypoglycemic clamp, bringing blood 
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glucose concentrations to 2.9mmol/l over 30 minutes, and remaining at 2.9mmol/l for 90 
more minutes 69.  Startlingly, unlike the dose response seen in their previous study, Davis 
et al. (2000) showed significantly decreased plasma glucagon and plasma epinephrine 
concentrations in all of the antecedent hypoglycemia groups, with no difference between 
these groups 69.  Although all hypoglycemia participants had a 30 minute duration of 
declining blood glucose concentration, only 5 minutes of sustained hypoglycemia was 
enough to cause a blunting of the counter-regulatory response to hypoglycemia on the 
subsequent day 69.  This gives a frightening impression that as incidences of 
hypoglycemia become more common and more severe, the chance of further autonomic 
failure increases. 
While the reduced counter-regulatory response to hypoglycemia is an interesting 
phenomenon in the healthy population, it becomes a true impediment to tightly 
controlling blood glucose concentration within individuals with DM 16,64,70.  A study by 
Dagogo-Jack et al. (1993) used a stepped hypoglycemic clamp with healthy individuals 
or individuals with IDDM, and observed a significantly reduced epinephrine and 
glucagon response from the individuals with IDDM 71.  However, it is known that 
individuals with IDDM lose responsiveness of pancreatic α cells, and rely more heavily 
on epinephrine during counter-regulatory responses to hypoglycemia.  Therefore, the 
researchers studied how individuals with IDDM responded to a stepped hypoglycemic 
clamp after either antecedent hypoglycemia or antecedent hyperglycemia 71.  Compared 
to individuals with IDDM who received antecedent hyperglycemia, the antecedent 
hypoglycemia group had a significantly blunted increase in plasma epinephrine 
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concentration 71.  This effect may even be related to long-term pharmacological 
suppression of blood glucose concentrations.  A study by Davis et al. (2009) studied how 
6 months of intensive therapy affected responses to 2 episodes of hypoglycemia 65.  In 
this study individuals with T2D were randomly grouped to either continue their normal 
diabetes treatment or undergo intensive treatment (combination therapy of metformin, 
glipizide XL, and acarbose) for 6 months 65.  The subjects were given 2 days of 
hypoglycemic clamps before, and 2 days of hypoglycemic clamps after the 6 month 
treatment, and compared to healthy individuals 65.  Before the intervention, the T2D 
group had no significant difference in epinephrine or glucagon compared to healthy 
controls, although all groups showed a blunted counter-regulatory response on day 2 65.  
However, after the 6 months of intensive therapy, the individuals with T2D had a 
significantly reduced epinephrine response on day 1, which was further suppressed on 
day 2 65.  Thus an impairment of counter-regulatory responses to pharmacologically 
produced hypoglycemia is problematic for individuals with T1D and T2D, however, 
another avenue for management of blood glucose concentration which is commonly 
recommended is lifestyle management 72-74. 
Antecedent Exercise and the Counter-Regulatory Response; Exercise is 
commonly recommended for health benefits as well as maintaining blood glucose 
concentrations for individuals with DM, but it has been shown that antecedent exercise 
can lead to inhibition of the counter-regulatory response to a subsequent hypoglycemic 
event 17,50,58,62,74,75.  This is similar to the suppression seen after antecedent hypoglycemia, 
which can also lead to the inhibition of the counter-regulatory response to a subsequent 
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bout of exercise 76-78.  These effects are not restricted to individuals with diabetes, but can 
also be seen in healthy individuals 61,78.  Although healthy individuals do not normally 
experience hypoglycemic excursions, individuals with diabetes are prone to them 
depending on their use of medication.  For this reason, aggressive treatment of 
hyperglycemia, through both medication and lifestyle management, must be limited to 
prevent a vicious cycle of hypoglycemia leading to worsening hypoglycemia with 
insufficient counter-regulatory responses 13,15,64. 
The mechanisms involved in antecedent exercise and the impact on subsequent 
hypoglycemia are not entirely understood.  Galassetti et al. (2001) showed that in 
humans, 2 bouts of 90 minutes of exercise at 50% VO2 max within the same day was able 
to decrease both glucagon and epinephrine response to a hyperinsulinemic hypoglycemic 
clamp 24 hours later 17.  In addition, the effects of the antecedent exercise were similar to 
antecedent hypoglycemia in both glucagon and epinephrine concentrations at the last 30 
minutes of the hypoglycemic clamp 17.  These effects have been attributed to changes in 
many different substances, including: lactate, beta-endorphin, and cortisol, however the 
exact mechanisms are not understood 44,79.   
The intensity and duration of antecedent exercise required to elicit the subsequent 
suppression of the counter-regulatory response has also been investigated, and seems to 
be more related to duration than intensity.  A study by McGregor et al. (2002) used 2 
bouts of 60 minutes of cycling at 70% VO2peak or rest in humans the day before a 
hypoglycemic clamp. While epinephrine and glucose infusion rates were significantly 
different in the antecedent exercise group compared to antecedent rest group during the 
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hypoglycemic clamp, there was no difference in glucagon 80.  It was hypothesized that the 
higher intensity of this study, compared with previous work by Galassetti et al. (2001), 
would lead to greater cortisol release and exacerbate the suppression of the counter-
regulatory responses 17,80.  The exercise sessions were sufficient to increase cortisol 
concentrations in the blood during the exercise, however, during the hypoglycemic clamp 
there were not any further reduced counter-regulatory responses compared to Galassetti 
et al. (2001) 17,80.  The authors suggested that the subjects who performed the 60 minutes 
at 70% were at a higher fitness level than most other studies, most of which have used 
lower intensities of exercise.  This may indicate that some effects seen acutely with 
exercise are eventually compensated for though training adaptations.  Another study in 
humans, by Sandoval et al. (2004), sought to test how two 90 minute bouts of exercise 
would affect the counter regulatory response at a lower intensity 18.  Sandoval et al. 
(2004) used the exercise protocol from Galassetti et al. (2001) at either 50% VO2 Max or 
30% VO2 Max.  Regardless of the training intensity, there was a significantly depressed 
counter-regulatory response to a hypoglycemic clamp on the following day.  Epinephrine, 
but not norepinephrine, was significantly lower during the hypoglycemic clamp.  In 
addition, the glucose infusion rate and rate of disappearance were higher in the previously 
exercised humans while endogenous glucose production was lower 18.  Additionally, 
there was no difference in insulin concentrations between groups, suggesting that the 
difference was not accounted for by increased insulin stimulated glucose uptake 18.  
Although, assuming exercise sensitizes tissues to insulin, the similar insulin concentration 
in the 2 groups may still have resulted in an increased responsiveness in tissues of the 
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previously trained group.  Taken together, it seems as though antecedent exercise can 
lead to a diminished counter-regulatory response on a subsequent day.  In addition, this 
effects seems less related to exercise intensity than to exercise durations, and potentially, 
the training state of the individuals engaged in exercise 17,18,80. 
Hypoglycemia, Exercise, and HAAF; In addition to antecedent exercise affecting 
subsequent hypoglycemia, antecedent hypoglycemia affects subsequent exercise, 
suggesting that these systems are related.  Davis et al. (2000) showed that healthy 
individuals, given antecedent hypoglycemia, had a reduced counter regulatory response 
to subsequent exercise compared to individuals given antecedent euglycemia 78.  During 
the subsequent exercise bout, glucagon, epinephrine, and norepinephrine were 
significantly depressed under the antecedent hypoglycemia condition compared to the 
antecedent euglycemia condition 78.  There was also a failure to reduce plasma insulin 
concentrations in the antecedent hypoglycemia group compared to antecedent euglycemia 
78.  The suppression of the counter-regulatory response to exercise after antecedent 
hypoglycemia is also seen in individuals with T1D 76,77.  Galassetti et al (2003) showed 
that antecedent hypoglycemia blunted the increase in epinephrine, norepinephrine, and 
glucagon in response to 90 minutes of subsequent exercise (24 hours later) among 
individuals with T1D 77.  It was later shown by Galassetti et al. (2006) that the 
suppression of these counter-regulatory hormones respond in a stepwise fashion to deeper 
antecedent hypoglycemic excursions, at least within individuals with T1D, similar to 
what was shown by Davis et al. (1997) with different magnitudes of hypoglycemia 66,76.  
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This would lead to increased risk of exercise-induced hypoglycemia in individuals with 
IDDM who become hypoglycemic due to prior exogenous insulin administration 15,57,63. 
The effects of antecedent exercise on subsequent hypoglycemia was also seen 
during the same day in individuals with T1D 19.  Humans with T1D who exercised for 90 
minutes at 50% VO2Max during euglycemia were given a hypoglycemic clamp 150 
minutes after exercise.  Similar to previous studies, the antecedent exercise group showed 
decreased epinephrine response to the hypoglycemic clamp 19.  In addition, the rate of 
endogenous glucose production was lower and glucose infusion rate was higher in the 
antecedent exercise group 19.  These results were compared to a morning euglycemia rest 
group, a morning hypoglycemia rest group, and a morning no treatment (control) group.  
The antecedent exercise group and antecedent hypoglycemia group showed similar 
depression of epinephrine in response to hypoglycemia compared to euglycemic and 
control groups 19.  This suggests that antecedent exercise and antecedent hypoglycemia 
may be affecting the counter-regulatory response through similar mechanisms. 
It is interesting that there is a blunting of the counter-regulatory response to either 
exercise or hypoglycemia, if one condition precedes the other.  It could be assumed that 
the counter-regulatory hormones (glucagon and epinephrine) are finite, and have become 
exhausted 81.  However, these hormones should be produced in adequate supply in alpha 
cells of the pancreas and the adrenal glands (respectively), and therefore it seems unlikely 
that they are the limiting factor.  In addition, individuals who routinely exercise have 
increased catecholamines during each of their exercise sessions.  Although there is a 
training response over time which requires less catecholamines to produce similar 
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responses.  If peripheral glands, such as adrenal medulla and pancreatic islets, are 
functioning properly, it may be that the inhibition of the counter-regulatory response to 
hypoglycemia is a problem related to the CNS rather than acute changes to these 
peripheral organs. Therefore, it is important to understand the contribution of the CNS to 
the regulation of blood glucose concentration, and the counter-regulatory response to 
hypoglycemia.   
In addition to the peripheral mechanisms, the CNS plays an important role in the 
regulation of blood glucose in healthy individuals.  The pancreatic islets are innervated 
by both parasympathetic and sympathetic nerves (the vagus and splanchnic nerves, 
respectively) 82.  Stimulation of the vagus nerve leads to an increase in insulin secretion 
from pancreatic β cells, while stimulation of the splanchnic nerve leads to an increase in 
glucagon secretion from pancreatic α cells and an inhibition of insulin secretion 82.  While 
the pancreas has some autonomous ability to regulate its own function, due to 
fluctuations in blood glucose concentrations and glucokinase activity, if the pancreatic 
nervous innervation is obliterated, the responsiveness to changes in blood glucose 
concentrations is significantly diminished 29,82,83.  This suggests that there are areas 
within the CNS that respond to changes in glucose concentrations and stimulate 
peripheral responses to regulate these concentrations.  Indeed, studies have shown that 
the counter-regulatory response can be blunted by increasing energy substrates, such as 
glucose or lactate, within the hypothalamus, despite systemic hypoglycemia 30,84.   This 
seems to suggest that glucose sensing portions of the hypothalamus may be able to 
regulate sympathetic efferents 24.  Therefore, the ability of neurons to alter their activity 
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in response to changes in blood glucose (or local glucose) concentration is important to 
the counter-regulatory response to hypoglycemia in both healthy individuals and 
individuals with DM.    
Glucose Sensing in the Brain  
The idea that the brain responds to the concentration of available glucose is not 
new and was established in the mid-1800s 85.  The glucose sensing activities in the brain 
encompass glucose-sensitive and glucose-responsive neurons, both of which alter their 
activity according to the concentration of glucose 86,87.  Glucose-responsive neurons [now 
referred to as glucose excitatory (GE) neurons], increase their rate of depolarization when 
glucose levels are high 86,87.  Glucose-sensitive neurons [now referred to as glucose 
inhibited (GI)], reduce their rate of depolarization while glucose is high, but increase 
activity when glucose becomes low 86,87.  These glucose sensing neurons are known to be 
present in several brain areas, specifically, the lateral hypothalamus, the arcuate nucleus, 
and the ventromedial hypothalamus (VMH) 82,83,86,88,89.  These areas of the brain are also 
thought to be associated with management of hunger and satiety.  While either GE or GI 
neurons may dominate some brain areas, both types may exist in the same area.  These 
neurons are known to produce changes in the systemic secretion of gluco-regulatory 
hormones by affecting both parasympathetic and sympathetic efferents.   
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Figure 2.3. Proposed Mechanisms of Regulation of Both GE and GI  Neurons 44.   
 
 
Glucose sensing neurons have been studied within the VMH, which is widely 
recognized as one of the most important regions within the hypothalamus involved in 
glucose sensing and the counter-regulatory response to hypoglycemia.  It is located near 
the third ventricle as well as the median eminence (see Figure 2.4), allowing it to sample 
both hormones which regulate glucose as well as glucose concentrations 30.  It is well 
established that both GE and GI neurons exist within this brain area 25,29,30,44,82-84,86,88-93. 
Figure 2.3 illustrates several proposed mechanisms by which the glucose sensing neurons 
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are thought to alter their activity based on glucose concentrations.  The current leading 
hypotheses related to the regulation and function of glucose sensing neurons focus on: 1) 
ATP sensitive potassium channels (KATP), 2) glucokinase and GLUT2, and 3) AMPK.  
The GE neurons contain GLUT3 and GLUT2 transporters, and rely on glucokinase to 
phosphorylate glucose entering the cell 30.  When local glucose concentrations increases, 
glucokinase activity increases which increases glycolysis and increases the ATP:ADP 
ratio causing the KATP channels to close which leads to extracellular Ca
2+ entering the cell 
and stimulating the release of neurotransmitter containing vesicles 30.  AMPK activity is 
more commonly associated with GI neurons, and is thought to act on the cystic fibrosis 
transmembrane conductance regulator (CFTR) through NO and cGMP when ATP:AMP 
ratio is low 29,82,83,88,92.  It is important to note that the mechanistic pathway(s) for these 
glucose sensing neurons has not been fully elucidated, nor is it clear if associated glial 
cells are involved in the regulation 82.  It is also important to note that all of the proposed 
mechanisms rely on changes in energy availability, which suggests that the exact energy 
source driving the response may be substrates other than (or in addition to), glucose. 
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Figure 2.4. Location of the Ventromedial Hypothalamus 94. 
 
 
Counter-Regulatory Response and the VMH 
Human Studies; While glucose sensing neurons reside in many brain areas, an 
area that is frequently studied with respect to the counter-regulatory response to 
hypoglycemia is the hypothalamus.  Human studies have used functional Magnetic 
resonance imaging (fMRI) and positron emission tomography (PET) scans to attempt to 
determine the areas in the brain that respond to changes in blood glucose concentrations.  
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Early studies using fMRI showed that ingestion of glucose results in a decrease in activity 
in the hypothalamus 95.  It was also shown that this decrease in activity was dose 
dependent, with less hypothalamic activity when greater amounts of glucose were 
ingested 96.  Interestingly, this effect is blunted in non-insulin dependent individuals with 
T2D compared to healthy controls 97.  The effect of hypoglycemia has also been tested 
using fMRI.  These tests have shown that healthy individuals have an increase in activity 
in the hypothalamus in response to hypoglycemia 98.  Individuals with T1D also showed 
an increase in activity in the hypothalamus in response to hypoglycemia, but to an even 
greater extent than the healthy individuals 98. However, the individuals with T1D still 
show reduced epinephrine and glucagon in response to hypoglycemia 98.  It is of note 
that, when fluorodeoxyglucose was used for PET scan of the brain, individuals with T1D 
and hypoglycemia unawareness showed reduced activation of the hypothalamus, and 
reduced blood epinephrine concentrations, compared to individuals with T1D with 
normal hypoglycemia awareness 99.  These studies cannot pinpoint the exact region of the 
hypothalamus that account for changes in brain activity in response to hypoglycemia, but 
the ventromedial hypothalamus is within the areas indicated.  To test these mechanisms 
further, the brain must be manipulated and tested in ways that would not be permissible 
in humans; therefore, animal studies are required. 
Animal Studies; Several studies have begun to unravel the role that glucose 
sensing neurons play in initiating the counter-regulatory response to hypoglycemia.  It 
was initially shown that injecting glucose into the VMH of rats during systemic insulin-
induced hypoglycemia would lead to a failure of the normal counter-regulatory 
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mechanisms 100.  This was attributed to the reduced concentration of norepinephrine in 
the VMH when glucose was administered 100.  However, norepinephrine is not the sole 
regulator of the counter-regulatory response in the VMH, as many other compounds have 
been implicated 30.  Under normal circumstances, it is thought that the neurotransmitter 
being released by GE neurons is GABA, inhibiting the sympathetic efferent innervation 
of pancreatic α cells and adrenal glands 30,101.  The changes in GABA concentrations in 
the VMH were linked to the state of the KATP channels [whether or not they were 
stimulated (closed)] 101.  When KATP were opened, there was low GABA release in the 
VMH and a systemic increase in epinephrine and glucagon in response to insulin-induced 
hypoglycemia 101.  However, during hypoglycemia performed in conjunction with GABA 
receptor agonists in the VMH, the counter-regulatory response was absent 101.  This effect 
was also observed when KATP  channels were closed and then GABA receptor antagonists 
were applied 101. These studies firmly establish the importance of glucose sensing 
neurons within the VMH in the counter-regulatory response, at least in rats.  However, 
KATP channels respond to ATP:ADP ratio, not glucose directly.  Therefore, it seems that 
other energy substrates could potentially stimulate similar responses. 
Glucose or Lactate Sensing;  The glucose sensing neurons in the VMH may be 
responsible for the diminished counter-regulatory response to hypoglycemia after either 
antecedent hypoglycemia or exercise, leading to autonomic failure.  A current question of 
interest is whether these neurons are directly sensing glucose, or whether energy status is 
being signaled to the neurons in another way.  Earlier research has shown that local L-
lactate perfusion in the VMH reduced systemic glucagon, epinephrine, and 
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norepinephrine in response to a hypoglycemic clamp in rats 25.  To determine whether or 
not these changes were due to the metabolic role of L-lactate, D-lactate was also perfused 
in the VMH, showing no changes in counter-regulatory response, indicating that the level 
of metabolic fuels other than glucose, could potentially be indicative of energy status 25.  
Since these findings were similar to effects seen in studies with GABA, it was further 
hypothesized that the effects of lactate were being mediated through the effects of GABA 
from GE neurons 24. A recent study by Chan et al (2013), investigated the effects of L-
lactate and GABA on the counter-regulatory response to hypoglycemia 24.  Previous 
studies have shown that increased GABA in the VMH leads to a reduced counter-
regulatory response to hypoglycemia 101.  Utilizing microdialysis probes to inject certain 
compounds and assessing changes in GABA, hormones, and glucose via a carotid artery 
catheter, Chan et al. (2013) reported that when lactate was injected into the VMH prior to 
a hypoglycemic clamp, there was increased GABA present in the VMH 24.  Along with 
the increased GABA concentrations, blood concentrations of glucagon and epinephrine 
were lower compared to control animals 24.  When neuronal lactate transporters (MCTs) 
were inhibited by microinjection of 4CIN, GABA levels were reduced 24.  Finally, the 
researchers used a GABA receptor antagonist in addition to L-lactate infusion, and while 
GABA was still increased, the counter-regulatory response of glucagon and epinephrine 
was restored 24.  This suggests that, during hypoglycemia, glucose sensing neurons in the 
VMH can take up L-lactate from an extra-cellular pool to influence their activity.  
Additionally, the presence or absence of specific cellular membrane lactate transport 
proteins suggests L-lactate was not necessarily being produced within the neurons.  For 
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this reason, the hypotheses for differential patterns of lactate flux have been suggested for 
the brain 102-107.  If lactate and/or local energy substrates are important to the HAAF 
response, and are potentially coming from outside the glucose sensing neurons, it is 
worth investigating mechanisms by which either hypoglycemia or exercise can influence 
energy availability and metabolism in the brain. 
Brain Glycogen, and Impairment of the Counter-Regulatory Response to 
Hypoglycemia; The effect of antecedent exercise or hypoglycemia on subsequent 
hypoglycemic counter-regulatory responses may be driven by an increased concentration 
of glycogen within the brain.  A recent study by Matsui et al. (2012) using rats, showed 
that there is an acute increase in brain glycogen after exercise in many different brain 
areas 108.  The animals ran on a treadmill at 20m/min until exhaustion (81.2 ± 2.7 min.).  
This was sufficient to decrease brain glycogen, and after 24 hours, many brain regions 
saw super-compensation of glycogen stores 108.  Significant changes were seen in whole 
brain as well as in the cortex, hippocampus, hypothalamus, cerebellum, and brainstem, 
however, the super-compensation in the hypothalamus was only seen at 6 hours post-
exercise 108.  These researchers also tested whether 3 weeks of running at the same 
treadmill speed for 60 minutes 5 days each week would show even greater glycogen 
super-compensation in the brain.  However, in this condition, only the hippocampus had 
increased glycogen. Unfortunately, the peak glycogen concentrations may have been 
missed, due to the timing of the measurement at 72 hours post-exercise 108.  Alternatively, 
super-compensation may be a transient adaptation that is lost once long-term adaptations 
occur 108. 
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In addition to super-compensation of brain glycogen in response to exercise, it has 
been shown that hypoglycemia can also lead to brain glycogen depletion, and subsequent 
super-compensation 109-112.  The effect of hypoglycemia on glycogen depletion and super-
compensation has been measured in both human and rat models 109,112.  However, the 
super-compensation has not been shown to be equal within all regions of the brain, but 
seems to be more pronounced within the hypothalamus 111.  Of course, this is the region 
of the brain most associated with regulating the counter-regulatory response to 
hypoglycemia. 
The changes seen in brain glycogen in both exercise and hypoglycemia suggest 
that this could be a common link by which both methods could provide an alternative 
substrate for neurons during a subsequent episode of hypoglycemia.  However, a major 
problem is that brain glycogen exists within glial cells rather than neurons, and these glial 
cells, unlike hepatocytes, do not express glucose-6-phosphatase to allow glycogen 
derived glucose to exit the cell.  However, as previously discussed, many researchers 
suggest that lactate could be the substrate providing the alternative fuel for neurons 
104,105,113,114.  These lactate-related hypotheses may have significant implications for how 
glucose sensing neurons respond to hypoglycemia and ultimately, may provide insights 
into the coordinated effort, at the level of the brain, to maintain blood glucose 
concentrations within a physiologically acceptable range.  This general hypothesis has 
become known as the astrocyte to neuron lactate shuttle (ANLS). 
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Astrocyte to Neuron Lactate Shuttle 
The mechanism by which systemic glucose concentrations relate to brain lactate 
and glucose sensing is important for understanding the counter-regulatory response to 
hypoglycemia, as well as why there may be an inhibition of the counter-regulatory 
response after hypoglycemia or exercise.  Glucose has long been known to be the 
preferred energy substrate of the brain; in fact, the brain uses about 25% of the total 
glucose consumed (at rest) during the day and around 20% of oxygen to meet its energy 
requirements 107.  However, the brain is composed of multiple cell types, mainly neurons 
and glial cells, the most abundant glial cells are astrocytes.  Both neurons and astrocytes 
have been shown to increase their metabolic rates during brain activity 115,116.   During 
excitatory stimulation of brain activity, there is an increased need for ATP production; 
however, there is an observed mismatch in the location of increased cerebral blood flow 
and brain glucose uptake, and the location of oxygen utilization 107,117,118.  While the brain 
takes up large amounts of glucose, it is also capable of oxidizing many metabolic 
intermediates from glucose 102,107.  Due to the mismatch in the localization of glucose 
uptake and oxygen use, as well as the effects of lactate infusions in the brain, hypotheses 
have been developed to describe how energy substrates may be used within the brain.   
The astrocyte to neuron lactate shuttle hypothesis (ANLS) suggests that when 
there is increased neuronal activity, astrocytes increase their glycolytic rate which 
produces lactate as shown in figure 2-5 115,116,119.  The lactate is then shuttled out of the 
astrocyte and taken up by neurons, which can convert the lactate to pyruvate to enter the 
TCA cycle.  Recently this model has been proposed to occur between oligodendrocytes 
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and neurons as well 120.  Several types of scientific evidence support this hypothesis; such 
as the relative expression of enzymes and their activity levels in astrocytes and neurons, 
the neuronal activity under different concentrations of metabolic intermediates, and the 
arrangement of cellular transport proteins.  Each of these will be discussed in more detail 
in the following paragraphs. Based on current scientific evidence, the ANLS hypothesis 
seems likely to occur within at least some brain areas, however its relevance to the HAAF 
response is unknown. 
 
 
 
Figure 2.5.  Model of the Lactate Shuttle Hypothesis121. 
 
 
Lactate production seems to be linked closely with brain activity, similar to 
observations for glucose and oxygen use.  When neurons are stimulated to repeatedly 
depolarize, adjacent astrocytes produce lactate at a greater rate than at rest 116,122,123.  This 
appears to be mediated through the sodium dependent glutamate transport within 
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astrocytes, which have processes that enwrap most synapses 115,119,123.  Astrocytes take up 
glutamate via sodium dependent transporters, and the excess sodium is exported via Na/K 
ATPase pumps, leading to an increased rate of glucose uptake and glycolysis within the 
astrocyte 123.  There are also increases in blood flow to the active regions of the brain, 
possibly mediated via α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors on purkinje cells 122.  It has also been suggested that astrocytes independently 
regulate blood flow through the production of vaso-active molecules from aracadonic 
acid 116.  The increased blood flow and astrocytic glycolysis leads to the production of 
lactate which can be exported from the astrocyte and used as fuel by neurons 115,123.  
Indeed, as AMPA receptors are stimulated on neurons there is an increase in lactate 
uptake due to increased lactate transporter translocation 124.  This seems to suggest a 
neural activity mediated mechanism for lactate shuttling from astrocytes, at least within 
some portions of the brain. 
The ANLS hypothesis is also supported by the presence of certain enzymes within 
astrocytes and neurons.  Recently, a study by Herrero-Mendez et al. (2009) showed that 
astrocytes express the enzyme 6-phosphofructo-2kinase/fructose-2,6-bisphosphatase-3 
(Pfkfb3), which generates fructose-2,6-bisphosphate, an activator of phosphofructokinase 
1 125.  This enhances the rate-limiting step in glycolysis, allowing a higher glycolytic rate 
107,125.  While neurons also express Pfkfb3, they express an ubiquitin ligase, anaphase-
promoting complex/cyclosome-Cdh1 (APC/C), which marks Pfkfb3 for proteosomal 
degradation, thus reducing its activity 125.  Because astrocytes have low APC/C activity, 
they are not affected, and are capable of a higher rate of glycolysis 107,125.  Herrero-
41 
 
Mendez et al. (2009) further tested the evidence for the ANLS by artificially increasing 
neuronal glycolytic rate by inhibiting APC/C in neurons, or up regulating Pfkfb3 in 
neurons 125.  In either case, neuronal glycolytic rates were enhanced, however this lead to 
increased oxidative stress and apoptosis 125.  The authors suggested that this increased 
oxidative stress is due to the redirection of glucose from the pentose phosphate shunt 
towards oxidative glycolysis 125.  This suggests that neurons require both high ATP and 
antioxidants for proper functioning.  Additionally, it suggests that not all oxidative 
metabolism in neurons is from glucose, since glucose is required for the pentose 
phosphate shunt 107,125.   
Additional evidence for the ANLS hypothesis comes from the documentation that 
the aspartate/glutamate carrier (part of the malate aspartate shuttle) is predominantly 
expressed in neurons but not in astrocytes, and that the pyruvate dehydrogenase complex 
is strongly inhibited in astrocytes, but active in neurons 126,127.  A study by Berkich et al 
(2007) used immunohistochemistry to examine the aspartate/glutamate carrier co-
expression with glial fibrillary acidic protein (GFAP), and found no over lapping 
fluorescence 126.  They confirmed this finding showing that bulk preparation of 
synaptosomal (neuronal) mitochondria were capable of producing aspartate in the 
presence of glutamate at a higher rate than astrocytic mitochondria, which co-express 
branched chain aminotransferase and GFAP 126. In addition, LDH isoforms have been 
compared between neurons and astrocytes, and while both contain the LDH1 isoform, the 
LDH-5 isoform was exclusive to astrocytes 119,128,129.  A study by Halim et al (2010) used 
immunohistochemistry in primary cell cultures and stained for LDH (both isoforms) and 
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observed a greater content of LDH within astrocytes than neurons 127.  They also 
measured greater pyruvate dehydrogenase complex activity in neurons 127.  Another 
study, by Bittar et al. (1996), used immunohistochemistry in human brain slices 
(collected 3-12 hour post-mortem) to stain for LDH1 and LDH5.  While they observed 
that astrocytes, which also stain for GFAP, expressed LDH5, they noted that greater 
numbers stained for LDH1 128.  While LDH1 favors conversion of lactate to pyruvate, 
LDH5 favors conversion of pyruvate to lactate 128-130.  This expression pattern supports 
the view that while neurons can oxidize fuel for energy, not all the fuel consumed is from 
glucose, and astrocytes may use glycolysis to provide substrates to neurons, as well as for 
oxidative phosphorylation. 
Additionally, the presence of glycogen in the brain may also support the ANLS 
hypothesis.  In adult animals, glycogen exists exclusively in astrocytes within the brain 28.  
However, astrocytes do not express glucose-6-phosphatase to release glucose into the 
extracellular space 28.  Initially it would seem intuitive that astrocytes would use the 
glycogen to meet their own energy needs, a situation that parallels what is seen in skeletal 
muscle fibers.  However, it was discovered that neurons, when cultured with astrocytes, 
could survive longer during glucose deprivation than when they were cultured alone 131.  
In addition, this effect was only seen when the astrocytes were pretreated with insulin or 
methionine sulfoximine to induce enhanced glycogen content 28,131.  Neuronal 
overstimulation also showed that astrocytes helped to maintain the neuron’s ability to 
produce compound action potentials 28,120.  When astrocytes with stored glycogen are 
present, the compound action potentials can be sustained for a longer duration before 
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failure 28,120.  Despite these studies, others have suggested that glycolysis within 
astrocytes is being sustained by uptake of glucose from circulation 122.  In either case this 
suggests that astrocytes are helping neurons to meet their metabolic needs, but evidence 
suggests that they must be transporting something other than just glucose.  These findings 
appear to further support the ANLS hypothesis.  But how is lactate movement 
coordinated within the brain? 
Monocarboxylate Transport Proteins 
Because of the potential importance of the movement of lactate in both brain 
metabolism and in the counter-regulatory response to hypoglycemia, monocarboxylate 
transport proteins (MCTs), has been heavily researched.  One area of research has 
focused on the MCTs that facilitate the movement of lactate in and out of cells.  More 
importantly, how expression of these transport proteins are affected under different 
conditions may improve knowledge of metabolic function in the brain and suggest novel 
targets for pharmacologic manipulations.  Therefore, further investigation of these MCTs, 
and how they are regulated under different conditions, is necessary. 
There are 14 identified MCTs, of which six have been functionally characterized 
and four have been shown to transport lactate coupled with a proton 121,132,133.  These are 
members of the Solute Carrier Family 16, but have different names because the MCTs 
were named based on their functional characterization, while SLC16 nomenclature was 
based on DNA sequencing 121.  The most important MCTs to the study of brain 
metabolism and lactate shuttling hypotheses are MCTs 1, 2, and 4.  MCTs 1, 2, and 4 
come from different genes [SLC16A1, SLC16A7, and SLC16A3 respectively] on 
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different chromosomes [1, 12 & 17, respectively (shown in figure 2-6) as red lines], and 
therefore have different properties. 
The MCTs vary in their function according to the specific properties of each 
MCT, allowing differential monocarboxylate transport in different tissues and cell types. 
The MCTs have the capacity to transport many substrates, including lactate, pyruvate, 
and ketones, however they have different affinities for these substrates, shown in table 2-
1 134.  The MCTs were characterized in Xenopus laevis oocytes, which have no lactate 
transport activity and do not contain CD147 (Basigin, a chaperone protein used by some 
MCTs), allowing the functional characterization of the MCTs 134.  MCT’s were 
characterized by microinjecting relevant cRNA for each MCT.  The individual properties 
of MCT1, MCT2, and MCT4 are discussed below.  The remaining characterized lactate 
transporting MCT, MCT3, is found only in the retinal epithelium and choroid plexus and 
does not seem to be associated with the central control of blood glucose concentrations or 
the ANLS, and therefore will not be discussed further 121,132.   
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Figure 2.6.  Location of the Genes for MCT1, MCT2, and MCT4. 
 
 
Table 2.1 The Relative Km Values Each MCT has for Different Substrates,  
 
Adapted from Halestrap et al. 2013 134. 
 
Substrate 
MCT1 
Km 
MCT2 
Km 
MCT4 
Km 
Approximate 
Plasma conc. 
L-lactate 3.5 0.74 28 1.5 
D-Lactate 27.5 - 519 - 
Pyruvate 1.0 0.08 153 0.06 
D-β-Hydroxybutyrate 10.1 1.2 130 0.06 
Acetoacetate 5.5 0.8 216 0.02 
 
 
MCT1 is found in most tissues in all species in which it has been studied 132. The 
Km of MCT1 for lactate, 3.5mM, is between those of MCT2 and MCT4 
133,134.  MCT1 is 
not associated with CD147, and its activity is based solely on the substrate concentration 
and pH inside and outside the cell 134.  Therefore, the MCT is responsive to changes in 
substrate concentrations, but can also respond to changes in pH.  The activity of MCT1 is 
very well characterized, and it is known that the co-transport of lactate and a proton must 
MCT1
MCT2
MCT4
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begin with the MCT in an “open” conformation 134.  The proton must attach to its active 
site first, followed by the lactate.  This induces a conformational change to the “closed” 
state, which allows the lactate and proton to be released on the opposite side of the 
membrane 134.  In the brain, MCT1 is the primary MCT on the endothelial cells which 
make up the capillaries of the blood brain barrier 133.  These transport proteins are present 
on both the lumen facing and basal lamina facing membranes of the endothelial cells 133.  
This lends support to the idea that excess lactate and protons can be exported back and 
forth between the brain and circulation via the astrocyte end feet and endothelial cells.  It 
has been suggested that this may be involved in activation dependent hyperemia in the 
brain, as well as maintaining pH by reducing excess protons from glycolysis 106,119,135.  
Therefore, MCT1 can be thought of as a general, bi-directional, lactate transporter found 
in most tissues. 
Not all MCTs seem to be bi-directional in nature like MCT1.  Because of its 
ability to take up lactate at lower concentrations, MCT2 primarily imports lactate, and 
can be found in tissues which can use lactate for fuel, such as: testis, spleen, heart, 
kidney, liver, and brain 134,136.  In the brain, MCT2 is present exclusively in neurons 133.  
MCT2 has the lowest Km for lactate of the MCTs, about 0.7mM.  Also, unlike MCT1, 
MCT2 is co-expressed with embigin, a chaperone protein that helps to integrate some 
MCTs into cell membranes 134.  It has even been suggested that MCT2 resides in the cell 
and is stimulated to translocate to the cell membrane during neuronal activation 124.  
MCT2 translocation seems to be regulated by similar mechanisms as the glutamate 
receptors 2 and 3 (GluR2/3) such as glutamate, glycine, and tumor necrosis factor alpha 
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(TNFα).  This allows neurons to increase MCT2 during times of increased stimulation 
and activity.  This MCT appears to be used to import lactate into neurons for oxidation 
134.  It has been suggested that MCT2 activity in the brain is controlled through 
translation rather than transcriptionally 137.  This may be accomplished through insulin 
and insulin like growth factor, which can access to the brain through the median 
eminence and third ventricle 137.  This lends support to the ANLS hypothesis due to 
MCT’s presence in neurons, but not astrocytes, as well as its potential translocation to the 
cell surface during neuronal activation. 
MCT4 is found predominantly in highly glycolytic tissues, and in the brain, 
MCT4 is almost exclusively present in astrocytes 133.  MCT4 has the highest Km for 
lactate, about 35mM 133.  MCT4 is unique however, because its Km for pyruvate is about 
153mM, whereas the other MCTs have affinities for pyruvate that are more similar to 
their affinity for lactate 134.  This unique feature prevents the loss of pyruvate from the 
cells expressing MCT4, thus allowing glycolysis to continue by converting pyruvate to 
lactate and an NADH to NAD+ 134.  It also functions to ensure that lactate transport only 
occurs when high concentrations of lactate are being produced in the cell via increased 
glycolysis.  Additionally, the higher Km for lactate can be overcome by the difference in 
pH that occurs as glycolysis continues to produce lactate and protons 129.  The proton 
gradient then pulls the transport of lactate, overcoming the higher Km relative to the other 
MCTs 129.  This has been observed in skeletal muscle where glycolytic fibers export 
lactate via MCT4 and oxidative fibers take in lactate via MCT1 for oxidation 134.  This 
observed lactate shuttle in other tissues as well as the localization and functionality of the 
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MCTs in the brain have lent support to the ANLS hypothesis that: astrocytes export 
lactate via MCT4, while neurons import lactate via MCT2 to provide energy for neurons 
133 
The arrangement of MCTs in the brain is intimately related to how energy 
substrates are being handled.  Because MCT1 is present in the astrocytic end feet and on 
endothelial cells, it is plausible that lactate can be moved between the brain and 
circulation.  The presence of MCT1 allows for lactate transport between the astrocytic 
end feet and circulation for either enhancement of hyperemia during increased brain 
activation, or for an additional energy substrate during physical activity or hypoglycemia, 
when systemic lactate is high 138.  However, there is also the presence of MCT2 on 
neurons, which makes it plausible that neurons are taking up lactate from the interstitial 
pool for oxidation.  The presence of MCT4 on astrocytes makes it plausible that under 
certain conditions, such as intense exercise or hypoglycemia, astrocytes may be able to 
export lactate produced from increased anaerobic glycolysis, or being imported from 
circulation.  It is unknown if the route of glycogen derived lactate efflux would lead to 
astrocytic end feet to promote hyperemia, interstitial lactate pools for neuronal uptake, or 
both, and is likely dependent on multiple factors.  A deeper study of MCTs may help to 
elucidate these mechanisms.  While different MCTs are differentially expressed in 
specific tissues and cell types, their total expression can be altered under different 
physiologic stimuli. 
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MCTs and Exercise 
The MCTs exist in many tissues, and although it is already well established that 
they are altered by exercise in skeletal muscle, the effect of exercise on MCT content and 
function in the brain is also of interest.  Due to the effects of lactate in the VMH on the 
counter-regulatory response to hypoglycemia, as well as the common recommendation of 
increased physical activity for individuals with DM, the effects of exercise on MCT 
expression may be important to understanding the HAAF response.  First, this review 
will discuss the known effects of acute exercise on MCT expression in skeletal muscles 
and the brain, followed by the effects of chronic exercise on MCT expression in skeletal 
muscles and the brain.  Also, the effects of diabetes on MCT expression will be briefly 
explored.  In addition, potential mechanisms of MCT regulation will be briefly discussed.   
Effects of Acute Exercise; It is well established that exercise can affect the 
expression of MCT proteins in skeletal muscles 22,26,27,134,139.  This is true for both acute 
exercise bouts as well as chronic exercise training 22,139.  Coles et al (2004), have shown 
that 2 hours of running on a treadmill at 21m/min and 15% grade increased MCT1 and 
MCT4 protein content in rat skeletal muscles 22.  Immediately after the single exercise 
session, MCT1 mRNA and protein increased in red and white gastrocnemius as well as 
the soleus 22.  However, MCT4 protein was only increased in red gastrocnemius and 
soleus muscles, this may have been due to the abundance of MCT4 already present in 
white gastrocnemius 22,136.  These increased protein contents were detected for 12 to 24 
hours post exercise 22.  This shows that acute exercise is able to rapidly stimulate changes 
in MCT expression in certain skeletal muscles. 
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The effect of acute exercise on MCTs has not been thoroughly examined in the 
brain.  To our knowledge, only one paper has studied this topic to date.  A recent study 
by Takimoto et al. (2014), showed that acute exercise can have effects on MCT 
expression in various brain regions 21.  This study used Sprague-Dawley rats that had run 
on a treadmill for 2 hours at 20m/min on an 8% grade, which represents an intensity of 
about 50-70% of their VO2max.  The rats were sacrificed using focused microwave 
irradiation, which stops all enzymatic activity to prevent changes in lactate concentrations 
post-mortem.  Different brain areas were removed and western blotted for MCT1, MCT2, 
and MCT4 and then compared to non-exercised rats 21.  Although MCT1 expression was 
increased in the cortex and hippocampus, there was no change in MCT1 in the 
hypothalamus 21.  MCT2 was increased in the hypothalamus at 5, 10, 18, and 24 hours 
post exercise as well as the hippocampus at 0, 5, and 10 hours post exercise and cortex at 
5, 10, 18, and 24 hours post exercise 21.  MCT4 was increased only within the 
hypothalamus at 5 and 10 hours post exercise 21. MCT2 and 4 are exclusively expressed 
in neurons and astrocytes respectively, and indicate a potential for increased lactate flux 
through the ANLS.  This could provide a mechanism for the counter-regulatory response 
to hypoglycemia following exercise similar to that seen by infusions of lactate 24,25,90.   
Lactate was also measured in the different brain regions (using a colorimetric assay) after 
varying exercise durations, and it was shown that lactate was increased in the 
hypothalamus after 90 minutes of exercise and after 120 minutes of exercise 21.  This 
paper does not, however, address whether this change in lactate was related to changes in 
catecholamines or glucagon peripherally (HAAF response).  In addition, they did not test 
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the counter-regulatory response to a subsequent bout of hypoglycemia, which has been 
seen in other studies.  Takimoto et al. (2014), also only measured MCTs in large brain 
areas, therefore, the increase may or may not have been localized to the VMH within the 
hypothalamus.  
Effects of Chronic Exercise; The chronic effects of exercise training on MCT 
content in muscle has also been studied to determine if the changes seen acutely were 
transient or cumulative over time.  A study by Dubouchaud et al (2000), used an exercise 
training model in humans 139.  These subjects exercised on cycle ergometers for 6 days a 
week at a heart rate estimated to be about 75% of VO2peak 
139.  The subjects were trained 
for nine weeks, and had pre and post muscle biopsies to ascertain the amount of MCTs in 
their skeletal muscle 139.  There was a significant increase in MCT1 and a non-significant 
increase in MCT4 in the vastus lateralis homogenates after training 139.  However, when 
sarcolemma-enriched samples were used in place of homogenates, there was a significant 
increase in both MCT1 and MCT4 139.  In addition, a recent review by Thomas et al. 
(2011) noted that in many training studies that have examined MCT content in skeletal 
muscles, the more trained the individual, the greater the MCT content within their 
muscles 27.  However the review by Thomas et al. (2011) also suggested that MCT 
changes may be more related to higher intensity exercise, which may also be related to 
the level of training in individuals 27. This suggests that chronic training adaptations may 
increase MCT protein content in skeletal muscle at least within humans.  
Fewer studies have examined the effects of chronic exercise on skeletal muscle 
MCTs using rats (a model that could be expanded to examine brain MCTs).  One 
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prominent study was performed by Baker et al. (1998) using 3 weeks of treadmill running 
at either high or moderate intensity 26.  Rats ran 5 days each week for 3 weeks at either 
21m/min on an 8% grade (moderate intensity) or 31m/min on a 15% grade (high 
intensity) 26.  After 3 weeks the animals were sacrificed and western blotting analysis was 
used to compare MCT1 within the skeletal and cardiac muscles between both groups, and 
control animals.  There was a 94% increase in MCT1 within the red gastrocnemius of the 
high intensity training group, but no change in the moderate intensity group 26.  However, 
there was no increase in MCT1 in the white gastrocnemius of either group 26.  
Alternatively, MCT1 content within the cardiac muscle increased by 36% in the moderate 
exercise group and 44% within the high intensity group when compared to control 
animals 26.  A more recent study by Nikooie et al. (2013) used a 7 week training protocol 
to examine skeletal and cardiac MCT1 and MCT4 in rats 140.  Their training protocol 
consisted of speeds starting between15-20m/min for 20 minutes each day and increasing 
to 30m/min for 35 minutes each day by the last 2 weeks 140.  Unfortunately, the grade of 
the treadmill was not included in the methodology.  The researchers found that exercise 
training had significantly increased MCT1 in sacrolemmal fractions of the extensor 
digitorumlongus (EDL) and soleus of the trained versus control animals, but saw no 
difference in cardiac muscle 140.  There were significant increases in MCT1 within the 
trained group for all three muscles when measuring mitochondrial fractions 140.  There 
was only a significant increase in MCT4 for the trained animals within the soleus 140.  
Therefore, it seems that there are chronic training adaptations that increase MCT protein 
content within certain skeletal muscles as well as cardiac muscle. 
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If these acute changes accumulate over time in skeletal muscle there may also be 
a chronic training effect on MCT expression in the brain.  A recent study by Aveseh et al. 
(2014), investigated the effects of 8 weeks of exercise training on MCT content in certain 
brain areas 20.  Using male Wistar rats, after running on treadmills 5 days/week for up to 
60 minutes each day, MCT1 and MCT2 were measured via western blotting in the cortex, 
hippocampus, and cerebellum 20.  These were compared with sedentary rats, as well as 
diabetic rats that were either exercise trained or sedentary.  This study showed no effect 
of training on MCT1 for the healthy rats, but there was an increase in MCT1 in diabetic 
exercise trained rats.  Additionally, both diabetic groups showed higher MCT1 content in 
cortex and hippocampus compared to both exercise trained and sedentary control rats 20.  
This same pattern was seen for MCT2.  The researchers followed this by measuring the 
counter-regulatory response to insulin-induced hypoglycemia.  The diabetic animals 
showed a HAAF response to the insulin-induced hypoglycemia compared to the non-
diabetic animals 20.  The authors hypothesized that this blunted response was due to the 
increased MCT content in the diabetic animals leading to greater lactate uptake.  They 
measured this by inducing hypoglycemia in the animals with insulin, and then giving an 
intraperitoneal injection of lactate.  The lactate was measured in the blood and in the 
brain at 10, 20, and 30 minutes post-injection.  At 30 minutes post-injection, there was 
significantly higher brain lactate in the diabetic animals compared to non-diabetic 
controls, and the trained diabetic animals had greater brain lactate than the diabetic 
controls 20.  This is congruent with studies that have shown lactate to blunt the counter-
regulatory response to hypoglycemia and possibly with studies showing increased lactate 
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transport after antecedent recurrent hypoglycemia 23.  However, the brain lactate 
measures were done for the whole brain, while brain MCT measures were done in 
specific brain regions.  Also, this may suggest that lactate comes from circulation rather 
than astrocytic glycogen.  It is unfortunate that particular brain regions that are more 
integral to glucose sensing, such as the VMH, were not measured.  While the HAAF 
response to antecedent hypoglycemia or antecedent exercise occur in both healthy and 
T1D individuals, there seems to be greater capacity for monocarboxylate transport among 
individuals with T1D compared to healthy controls 110,112.  If this is correct, then the 
ANLS in individuals with DM may have a higher capacity to shuttle lactate to glucose 
sensing neurons to increase GABA and prevent the counter-regulatory response to either 
hypoglycemia or exercise. 
MCTs and Diabetes;  There is also some evidence that MCT expression is altered 
in individuals with diabetes compared to healthy individuals regardless of exercise.  
Aveseh et al. (2014) showed that the STZ induced diabetic animals had elevated MCT 
content in the sampled brain regions compared to the control animals before any exercise 
intervention was given.  Exercise training actually seemed to increase the MCT content 
slightly in both groups.  The previous study showed an increase in brain MCT1 and 
MCT2 in diabetic animals following exercise training 20.  However, the change in MCT 
content may be due to chronic hyperglycemia or ketosis seen in STZ induced rats 141.  
Another study by Canis et al. (2008) also used STZ induced diabetes to study the effect 
of hyperglycemia on MCT1 in the brain 141.  This study showed increases in MCT1 
protein content in many brain areas of the hyperglycemic rats compared to 
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normoglycemic rats, including a 12.3% increase in the hypothalamus 141.  In addition, the 
researchers ran correlations between local cerebral glucose utilization and MCT1 content 
and showed an r=0.70 for hyperglycemic rats and r=0.66 for normoglycemic rats, 
suggesting that local glucose concentrations can influence changes in MCTs in the brain 
141.  This suggests that glycemia may be more important for regulation of MCTs than 
diabetes per se, as other studies have induced changes in brain MCTs with high fat diets, 
but not diabetes 142.  A study by Pierre et al. (2007) fed mice either standard chow or high 
fat diet for 8 weeks and measured MCT1 and MCT2 in several brain areas 142.  The 
researchers measured increased MCT1 and MCT2 protein in the brain area containing the 
hypothalamus within the high fat diet animals compared to controls 142.  The weight, 
glucose concentrations, and insulin concentrations of the animals were tracked over the 8 
week period, and, while the high fat diet rats were heavier and had greater glucose 
concentrations, they were still producing insulin, unlike STZ induced diabetic animals 142.   
The researchers also examined control mice compared to db/db mice and ob/ob mice 142.  
They showed, within the same brain region, that both db/db and ob/ob mice had 
significant increases in MCT1and MCT2 compared to controls 142.  It is also of note that 
the high fat diet mice, db/db mice, and ob/ob mice all had significantly increased body 
weight compared to controls, which may also play a role in MCT expression.  
Researchers also suggested that high fat diet induced some MCT4 expression in neurons, 
however, changes in MCT4 were much smaller than those of MCT1 and MCT2 142.  
These data seem to suggest that changes in the MCT content in brains of animals with 
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diabetes may be more related to chronic increased glucose concentrations in the blood 
and brain, or possibly increased body weight. 
Other studies have shown reduced skeletal muscle MCT1 and MCT4 in STZ 
induced diabetic animals compared to control animals 140.  It is unknown why MCTs 
increase in the brains of diabetics, but decrease in muscle.  It may be due to MCT’s role 
in transporting other molecules such as β-hydroxybutyrate. In studies of exercise training 
and examining skeletal muscle, MCT1 content was increased in individuals and animals 
with diabetes after exercise training 140,143.  However, there is no consensus on whether 
MCT4 increases or decreases in skeletal muscle after exercise training in a diabetic 
model 140,143.  Again, these changes may be related to body weight or blood glucose 
concentrations.  In the study by Nikooie et al. (2013), there was reduced MCT1 in EDL, 
soleus, and heart of diabetic animals, but trained diabetic animals’ levels of MCT1 were 
preserved, and not significantly different from control animals 140.  However, the trained 
diabetic animals also had significantly lower blood glucose concentrations compared to 
the diabetic animals, and significantly lower body mass, however body mass was not 
different from control animals 140.  Because of the differential effects on MCTs in muscle 
or brain, and under different metabolic conditions, it is important to continue to 
investigate the effects of exercise training in different tissues. 
Mechanisms of MCT Expression; The mechanisms behind the increase in MCTs 
in skeletal muscle are not entirely known.  It has been proposed that AMPK signaling is 
one of the mechanisms leading to this up-regulation 144.  A study by Kitaoka et al. (2014) 
used rats with denervated gastrocnemius muscles, and then injected the muscle with 
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either saline or AICAR [AMPK activator] 144.  After seven days, the innervated muscles 
that had received AICAR had significantly higher MCT1 and MCT4 protein content 
compared to the innervated, saline treated, muscles 144.  Compared to control, there was 
no effect on MCT1 protein content when muscles were denervated regardless of whether 
AICAR treatment was applied 144.  However, the denervated muscle that received saline 
had significantly less MCT4 than the control, while the denervated muscle that received 
AICAR was not significantly different than control 144.  This indicates that AMPK may 
be one of the mediators for up-regulation of some MCTs, at least in skeletal muscle.  It is 
unknown whether this would be true in brain.  A study by Chenal et al. (2008) showed 
that IGF and insulin could increase MCT2 activity (measured by green fluorescent 
protein) in neuronal cell cultures 137.  This seemed to be mediated through the Akt, 
mTOR, p70S6K pathway 137.  However, this pathway would be inhibited by AMPK 
signaling via tuberous sclerosis complex 2, therefore, MCT2 (unexpressed in skeletal 
muscle) may be regulated differently than other MCTs or perhaps, brain MCTs may be 
regulated differently than muscle MCTs 145,146. 
Lactate and hypoxia have also been suggested as mediators of changes in MCT 
protein content within skeletal muscles 147-149.  A study by Hoshino et al. (2014) 
examined 3 weeks of treadmill running at 25m/min for 40 minutes each day, 6 days a 
week in mice 149.  The mice were fed either saline or sodium lactate after each exercise 
session, and increased blood lactate levels were confirmed with a lactate meter 149.  The 
mice who received lactate showed greater MCT1 in white gastrocnemius as measured by 
western blotting 149.  Unfortunately, there was no sedentary group to compare, but it 
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seems that lactate concentrations were somewhat related to MCT1 expression in white 
muscle 149.  Another recent study by De Araujo et al (2015) used swim exercise in mice at 
the highest relative intensity to maintain blood lactate levels at a steady state 147.  After 25 
minutes of swimming a group of mice were sacrificed either immediately, after 5 hours, 
or after 10 hours 147.  MCT1 in the heart was increased relative to control mice after 10 
hours, while MCT1 in the soleus was increased at all three time points compared to 
control mice 147.  MCT1 in the red gastrocnemius did not change, and was only increased 
immediately after exercise in the white gastrocnemius 147.  MCT4 did not change in red 
or white gastrocnemius, but was increased in soleus immediately after exercise and 10 
hours after exercise (but not 5 hours after exercise) in exercised compared to control mice 
147.  However, again, the lack of a group that exercised at lower blood lactate levels 
makes it difficult to interpret the results of this study. 
Another potential mediator of MCT expression in skeletal muscle during or post-
exercise may be hypoxia.  A recent study by Millet et al. (2014) compared human cyclists 
who trained under normoxic or hypoxic conditions (similar to altitude of ~3000 m) 150.  
However, after 3 weeks of training, neither the normoxic nor hypoxic group showed 
significant differences in MCT1 or MCT4 within the vastus lateralis 150.  The authors 
suggested that there may not have been a strong enough stimulus for change in MCT 
content, or that the population studied (young, trained men with VO2Max~58ml/kg/min) 
have limited room to further increase MCT content 150.  A more recent study by Saxena et 
al. (2016) used swim training in rats to examine the effects of exercise with or without 
pre-treatment with CoCl2 (which stabilizes HIF-1α) 
148.  The rats swam for 6 days each 
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week, starting at 30 minutes per day and increasing by 10 minutes each day until reaching 
60 minutes 148.  The training continued for 15 days with one group receiving 10 mg/kg 
CoCl2 2 hours before their exercise session 
148.  Only the red gastrocnemius was analyzed 
for mRNA as well as protein content.  There was significantly more mRNA for MCT1 in 
the CoCl2 control group compared to the saline control group, and significantly less 
mRNA for MCT2 and MCT4 148.  The trained group had greater mRNA for MCT1 
compared to controls, but the CoCl2 trained group had significantly more than all other 
groups 148.  The trained group had more MCT2 mRNA than all other groups, while the 
CoCl2 trained animals had greater than control, but less than the trained 
148.  The trained 
animals had less MCT4 mRNA compared to controls, and the CoCl2 trained animals had 
less MCT4 mRNA than all other groups 148.  When protein was assessed, similar patterns 
were seen, with the CoCl2 controls having greater MCT1 than controls, and less MCT2 
and MCT4 148.  The trained animals showed greater MCT1 and MCT2 compared to 
controls, while CoCl2 trained animals had greater MCT1 compared to all other groups, 
and MCT2 greater than control, but less than trained 148.  Finally, the trained animals had 
less MCT4 than controls, and the CoCl2 trained animals had less MCT4 than all other 
groups 148.  The researchers also confirmed the increased amounts of HIF-1α and PGC-1α 
in the CoCl2 treated animals 
148.  Unfortunately, the researchers did not include other 
tissues, or even other muscles, as different adaptations may have been observed.  The 
results are in partial agreement with other studies that examine MCTs and hypoxia.  A 
recent study using human adipocytes showed increased mRNA for MCT1 and MCT4 but 
reductions in MCT2 when exposed to CoCl2 
151.  This lends support to the idea that 
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exercise induced hypoxia may be partially responsible for increases in MCT proteins 
observed after exercise or exercise training.  
Conclusions 
There is little information about how exercise training or hypoglycemia affect the 
expression and overall protein content of MCTs in the VMH as well as how this may 
relate to the HAAF response.  If there are increases in MCTs in the hypothalamus, as well 
as changes in glycogen content in astrocytes, there is reason to believe that the glucose 
sensing activities of the VMH may be affected via the ANLS.  However, because lactate 
has been shown to blunt the counter-regulatory response to hypoglycemia, it is unknown 
whether these adaptations would positively or negatively affect individuals with T1D or 
T2D.  While the adaptation seems negative, it is protective of the neurons when glucose 
becomes low.   
While exercise is commonly prescribed to individuals with T2D to help regulate 
their blood glucose concentrations, individuals with DM often have problems with 
hypoglycemia after exercise [either immediately or delayed by hours].  In addition, tight 
pharmacological control of blood glucose concentrations is recommended to prevent 
diabetic complications 16.  Both of these treatment methods may potentially lead to 
increased incidence of hypoglycemia.  This is due to increased glucose uptake in skeletal 
muscle via contraction stimulated or insulin stimulated GLUT4 translocation, as well as 
improved insulin sensitivity 54,152.  Whether or not some or all of the MCTs are up-
regulated after either exercise or hypoglycemia may affect an individual’s ability to 
respond to a subsequent episode of hypoglycemia.  If this is the case it would give 
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another compelling piece of evidence for the recommendations for physical activity and 
exercise among individuals with T1D or T2D, as well as how glycemia should be 
pharmacologically managed.  It may also offer a new target for pharmacological research 
for brain metabolism, as well as treatment of individuals with IDDM who are likely to 
experience HAAF in response to hypoglycemia or exercise. 
 
 
 
 
 
 
 
 
 
62 
 
CHAPTER III 
 
CHRONIC AEROBIC TRAINING IN RATS DOES NOT ALTER MCT CONTENT 
WITHIN THE VENTROMEDIAL HYPOTHALAMUS  
 
 
Abstract 
While lactate was once considered to be a metabolic waste product, it is now well 
established that lactate can be used as a metabolic fuel by several tissues to produce 
pyruvate and enter the TCA cycle.  Several tissues have been shown to “shuttle” lactate 
to other tissues for energy.  This has been shown in skeletal and cardiac muscles as well 
as within the brain.  Lactate is shuttled between cells via monocarboxylate transport 
proteins (MCTs).  Acute aerobic exercise as well as short term training has been shown to 
increase MCTs within cardiac and skeletal muscles.  The effects of exercise on MCTs 
within the brain, particularly the ventromedial hypothalamus (VMH) which helps 
regulate the energy status of the body, have been inconclusive.  Therefore, the objective 
of the current study was to determine whether 6-7 weeks of aerobic exercise training 
would increase MCT protein content within the VMH as well as skeletal muscles.  It was 
hypothesized that aerobic exercise training would increase MCTs in skeletal muscle, 
cardiac muscle, and within the VMH.  Sprague-Dawley rats (males) were acclimated to 
treadmill running and trained for 6-7 weeks with a progressive protocol which plateaued 
at the end of week 4.  After 6-7 weeks of training, animals were euthanized and had their 
VMH, red and white gastrocnemius, and cardiac muscle removed for western blotting of 
MCT1, MCT2, and MCT4.  While training status was confirmed via increased 
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cytochrome C oxidase activity in the red and white gastrocnemius of the trained versus 
sedentary rats (Λ =0.521, p=0.01), there were no changes in MCT1, MCT2, or MCT4 
within red or white gastrocnemius, cardiac muscle, or the VMH.  These findings were 
somewhat surprising for muscle, which have previously been shown to increase MCT1 
and MCT4 in response to exercise training.  However, this was somewhat congruent with 
another study which showed no increase in MCTs within other brain areas after 8 weeks 
of training.  Although it is uncertain whether MCTs change acutely after exercise, there 
seems to be no sustained chronic increase in MCTs within the VMH after 6-7 weeks of 
aerobic training. 
Introduction 
Aerobic exercise increases the metabolic demands on the body, requiring 
increases in ATP production to maintain muscle movements and cardiac output.  As 
exercise intensity increases, increased glycolysis can lead to the production of lactate and 
protons, as well as local hypoxic conditions.  Monocarboxylate transport proteins 
(MCTs) move a lactate molecule and a proton across cell membranes.  Different MCTs 
are expressed in different cell types to enhance either uptake or efflux of lactate (and 
potentially other molecules such as ketones) 121,134,153-156.  Highly glycolytic tissues, such 
as white skeletal muscle, express more MCT4 to export lactate during high glycolytic 
activity while more oxidative muscle fibers express higher concentrations of MCT1 to 
allow import of lactate to be used for oxidative phosphorylation 121,134.  It has been shown 
that acute and short term exercise training leads to changes in MCT content in several 
tissues 22,26,27,139,157,158.  In addition, hypoxia or exercise with pretreatment with CoCl2 
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increase the expression and protein content of MCTs 1 and 4 148,151.  However, it remains 
controversial as to whether adaptations in MCTs occur with exclusively high intensity 
exercise or whether the exercise needs to be exhaustive, regardless of intensity 27.   
MCTs are expressed in many tissues throughout the body in addition to skeletal 
muscles 134,136,159.  MCTs are even found within the central nervous system, where 
different cell types in the brain differentially express various MCTs 160,161.  Neurons 
primarily express MCT2 while astrocytes, and possibly oligodendrocytes, express MCT1 
and MCT4 104,114,160.  It has been suggested, based on the distribution of MCTs as well as 
other metabolic enzymes expressed in astrocytes or neurons, that lactate is produced in 
astrocytes via glycolysis and/or glycogenolysis and then shuttled via MCTs to neurons 
for oxidative phosphorylation 104,114,162.  This hypothesis has become known as the 
astrocyte to neuron lactate shuttle (ANLS).   
Exercise has been shown to increase MCT mRNA and protein in skeletal and 
cardiac muscles 22,158.  Baker et al. (1998) showed that MCTs increase in several skeletal 
muscles, as well as cardiac muscle over a 3 week treadmill training protocol in rats 26.  
Another study showed increased MCTs in skeletal muscle after only a single exercise 
session on a treadmill in rats 22.  However, few studies have investigated whether exercise 
has a similar effect on MCTs in the brain 20,21.  A study by Takimoto et al. (2014) showed 
rapid (within 5 hours) increases in MCT protein content after a single exhaustive exercise 
bout in several brain areas, including the hypothalamus 21.  However, a study by Aveseh 
et al. (2014) showed that exercise training did not cause increases in MCT1 or MCT2 in 
any areas of the brain measured in the study20.  In consideration of these dichotomous 
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results, it must be noted that Aveseh et al. (2014) took measurements 48 hours after the 
last exercise session, which means they may have missed the more acute changes seen by 
Takimoto et al (2014) 20,21.  Unfortunately, while Aveseh et al. (2014) did not measure 
MCT changes in the hypothalamus as Takimoto et al. (2014) did, they did measured the 
counter-regulatory response to hypoglycemia, which Takimoto et al. (2014) did not.  
However, an important brain region involved in central regulation of blood glucose 
concentrations is located in the ventromedial hypothalamus (VMH), and this area was not 
assessed by Aveseh et al. (2014) 30.  Thus, a gap in the literature remains related to 
chronic aerobic training and the potential influence on MCT protein content within the 
VMH. 
To fill this gap in the literature, the purpose of the current study was to determine 
whether 6 to 7 weeks of regular aerobic exercise leads to changes in MCT1, MCT2, or 
MCT4 within the VMH.  In addition, this study will add to the general body of 
knowledge of how chronic aerobic exercise affects MCT content within the brain and 
skeletal muscles. It was hypothesized that aerobic exercise training would lead to 
increases in MCTs 1, 2, and 4, similar to observations by Takimoto et al. (2014) 21. This 
was expected because the current investigation minimized the time between exercise and 
removal of the brain compared to the study by Aveseh et al. (2014) (5 hours post exercise 
versus 48 hours), and because Baker et al. (1998) showed that 3 weeks of training 
affected MCT1 and MCT4 protein content in cardiac and skeletal muscles 20,26. 
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Methods 
Animal Acclimatization and Exercise Training;  All male Sprague-Dawley rats 
were received and allowed to acclimate to the animal facility for a week before 
acclimation to the treadmill began.  Rats were housed alone on a 12:12 hour light dark 
cycle.  Throughout the study, the animals had ad libitum access to food from 4pm until 
9pm (mid dark cycle until 1 hour before light cycle).  The animals were also fed 90 
minutes after their exercise (or sedentary) bout (1 hour after the beginning of the dark 
cycle).  The acclimation to the treadmill lasted for 5 consecutive days (from Monday to 
Friday) and increased the duration and intensity as follows: Day1, 5min. 10m/min, Day2, 
5min. 15m/min, Day3, 5min. 15m/min and 5min 20m/min, Day4, 10min. 20m/min, 
Day5, 15min 20m/min.  After the week of acclimation to the treadmill, rats were 
separated into groups based on how well they acclimated to treadmill running.  
Therefore, rats were not truly randomized, rather, rats that would not run on the treadmill 
during acclimation became the sedentary group.  The rats were then run for 6-7 weeks 
with increasing intensity until plateauing during week 4 (Table 3.1).  The treadmill 
remained at an incline of 10.5% throughout the entire study.  The sedentary rats were 
placed on a stationary treadmill, in the same room and at the same time of day, during the 
exercise period each day.  The exercise sessions were scheduled to end at the same time 
each day (approximately 10 AM) as the duration increased. Therefore, the exercise 
occurred in the last hour of the rat’s light cycle, while they were over-night fasted. 
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Table 3.1. The Progressive Endurance Exercise Training Protocol. 
 
 Day 1 Day 2 Day 3 Day 4 Day 5 
Week 1 
15min. 
20m/min 
25min. 
20m/min 
25min. 
20m/min 
5min. 
25m/min 
20min. 
20m/min 
10min. 
25m/min 
25min. 
15m/min 
15min. 
25m/min 
Week 2 
25min. 
15m/min 
15min. 
25m/min 
30min. 
25m/min 
35min. 
25m/min 
40min. 
25m/min 
45min. 
25m/min 
Week 3 
50min. 
25m/min 
55min. 
25m/min 
60min. 
25m/min 
60min. 
26m/min 
60min. 
27m/min 
Week 4 
60min. 
28m/min 
60min. 
29m/min 
60min. 
30m/min 
60min. 
30m/min 
60min. 
30m/min 
Week 5 
60min. 
30m/min 
60min. 
30m/min 
60min. 
30m/min 
60min. 
30m/min 
60min. 
30m/min 
 
 
Tissue Removal and Processing; The rats were sacrificed approximately 5 hours 
after their last exercise session by injection of pentobarbital and having their heart 
removed (part of another study).  The choice of the 5 hours post-exercise timeframe for 
sacrifice was based on Takimoto et al. (2014) which reported increases of MCT2 and 
MCT4 by 5 hours after acute exercise. By sacrificing 5 hours after the last exercise 
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session, any acute increases in MCTs should be observed.  The head was immediately 
removed, and the brain was extracted.  The VMH (including the ventromedial nucleus, 
the arcuate nucleus, and the median eminence as shown in figure 3-1) was removed and 
placed in a -80°C freezer until tissue preparation.  In addition gastrocnemius, was 
harvested. Following ischemia reperfusion testing of the hearts for another study, the 
cardiac tissue was also frozen and stored for analysis. 
 
 
 
Figure 3.1 Area of Brain Taken for Analysis of MCTs within the VMH. 
 
 
A sub-set from each group of rats had their gastrocnemius removed for the 
cytochrome c oxidase assay, as a verification that aerobic training adaptations occurred.  
The cytochrome c oxidase assay was performed with both red and white gastrocnemius.  
The muscles were homogenized in a buffer of 50mM KH2PO4, 0.1mM EDTA, and 0.1% 
Triton X-100 (pH7.4).  The samples were kept constantly on ice until they were 
centrifuged at 4044 RPM (1,500 RCF) for 10 minutes.  The supernatants were collected 
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and analyzed for cytochrome c oxidase activity using a Clark-type oxygen electrode and 
determined via polarography as performed by previous studies 163,164.   
MCTs were assessed in brain tissues as well as skeletal and cardiac muscles of the 
trained versus sedentary rats.  The VMH was homogenized with a glass mortar and pestle 
on ice using a RIPA buffer (appendix A).  Protease inhibitors as well as phosphorylase 
inhibitors were also added to prevent any degradations or alterations of proteins in the 
lysate.  After homogenization, the samples were sonicated 3 times each to further disrupt 
any cell membranes.  The samples were centrifuged for 15 minutes at 14,000 RPM 
(18,407 RCF) afterward, supernatants were collected and stored at -80°C until used for 
western blotting.  Gastrocnemius, soleus, and cardiac muscles were homogenized in 
RIPA buffer, including phosphatase and protease inhibitors, using a Pro Scientific 
homogenizer (Pro200, Pro Scientific Inc. Monroe, CT) and then sonicated 3 times each.  
The lysates were centrifuged for 15 minutes at 14,000 RPM (18,407 RCF).  The 
supernatants were collected and stored at -80°C until used for western blotting analysis.  
Recovery rate for MCTs was estimated at 50% when comparing supernatant to re-
suspended pellets.   
Total Protein Assessment; A BCA assay (Pierce BCA Protein Assay Kit) was 
used to assess the total protein content within each sample.  When running the western 
blotting assays, 50µg of total protein from each sample was added to each lane.  
Electrophoresis was run overnight at 60 volts.  Proteins were then transferred to a PVDF 
membrane over 6 hours at 200 milliamps. 
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Western Blot Procedures; Samples were run for MCT1, MCT2, and MCT4 using 
primary antibodies purchased from Santa Cruz Biotechnology (sc-50325, sc-50323, and 
sc-50329 respectively).  Antibodies were applied to VMH samples in 5% milk at 1:200 
for MCT1, 1:500 for MCT2, and 1:75 for MCT4 on a rocker overnight in a 4°C cooler.  
Antibodies were applied to skeletal muscle samples in 5% milk at 1:200 for MCT1 and 
1:250 for MCT4 on a rocker overnight in a 4°C cooler.  Antibodies were applied to 
cardiac muscle samples in 5% milk at 1:500 for MCT1 on a rocker overnight in a 4°C 
cooler.  A secondary antibody for all samples used anti-rabbit (Pierce 31460) and was 
applied in 5% milk at 1:5000 on a rocker for 2 hours at room temperature.  Blots for 
VMH were exposed in a BioRad Chemidoc station for 140 seconds for MCT1, 200 
seconds for MCT2, and 200 seconds for MCT4. Blots for red and white gastrocnemius 
were exposed for 160 seconds for MCT1 and 140 seconds for MCT4.  Blots for cardiac 
muscle were exposed for 200 seconds for MCT1.  After initial exposure, PVDF 
membranes were stripped and probed with primary antibody for GAPDH (sc-166545).  
Antibody was applied in 5% milk at 1:4000 on a rocker overnight in 4°C cooler.  
Secondary antibody for anti-mouse (Pierce 31450) was applied in 5% milk at1:2000 on a 
rocker for 2 hours at room temperature.  Blots for GAPDH were exposed in a BioRad 
Chemidoc station for 40 seconds.  In addition, there were a subset of rats whose white 
and red gastrocnemius and cardiac muscles were blotted with the same concentration of 
antibody and exposure time to examine MCT1 distribution across tissues with different 
oxidative capacity. 
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Bands from western blots were quantified using densitometry tools on Quality 
One software.  The same researcher performed all densitometry without knowing which 
bands represented which animals.  A ratio of MCT to GAPDH was determined, and a 
natural log transformation was used to normalize all data, to account for non-normal 
distribution of ratio data, and shifted up by 10 arbitrary units (ie, 
ln[(MCT:GAPDH)]+10).  Further description of the western blotting procedure can be 
found in Appendix B. 
Statistical Analyses; Statistics were run using SPSS version 23 (IBM, Armonk, 
New York).  MANOVAs were used as an overall test of significance for the multiple 
dependent variables.  If MANOVAs were significant, follow up ANOVAs were run for 
each dependent variable for interpretation.  A MANOVA was run for cytochrome c 
oxidase activity in red and white gastrocnemius of exercise trained and sedentary rats.  A 
MANOVA was run for MCT1 and MCT4 in red and white gastrocnemius in exercise 
trained and sedentary animals using body mass as a covariate.  A MANOVA was run for 
MCT1, 2, and 4 in the VMHs of exercise trained or sedentary rats, using body mass as a 
covariate.  Follow up ANOVAs were run for any significant MANOVAs.  One-way 
ANOVAs were run for cardiac MCT1 and body mass between exercise trained and 
sedentary rats.  An additional one-way ANOVA was run for a sub-sample of tissues of 
varying oxidative capacity (white and red gastrocnemius and cardiac muscle) for MCT1 
with a Tukey post-hoc test.  ANOVA, F and p values are reported for all tests, but only 
ANOVAs within significant MANOVAs should be interpreted. Significance was set at 
p=0.05 a priori. 
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Results  
A total of 24 rats started the training paradigm. All but one of the rats completed 
the training protocol.  A trained rat was injured and could not continue to run, this rat was 
excluded from the final analyses.  There was not a statistically significant difference in 
body mass between the trained and sedentary group, although this comparison was close 
to significance (374.2 ± 7.4g vs.399.6 ± 10.3g respectively) (F=3.95, p=0.053).  A sub-set 
of the trained group of rats (n=9) were shown to have increased cytochrome c oxidase 
activity within both the red and white gastrocnemius compared to a sub-set (n=9) of the 
sedentary group (Λ=0.338, p<0.01).  There was a significant improvement in cytochrome 
c oxidase activity in the trained group in red gastrocnemius (F=27.967, p<0.01) as well as 
within the white gastrocnemius (F=11.579, p<0.01) as shown in Figure 3.2.  When 
controlling for body mass, there was a significant overall effect on cytochrome c oxidase 
activity (Λ =0.521, p=0.01). However, when comparing this effect in individual tissues, 
the effect of body mass on cytochrome c oxidase activity was only significant within the 
white gastrocnemius (F=12.537, p<0.01).  Finally, there was no difference in 
gastrocnemius mass : body mass ratio among this subset of runners (5.42) and sedentary 
rats (5.10) (t=-1.13, p>0.05). 
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Figure 3.2.  Cytochrome C Oxidase Activity in the Gastrocnemius. 
 
(* indicates difference from sedentary group, p<0.05) 
 
 
There was no overall (MCT1 red, MCT4 red, MCT1 white, MCT4 white = group 
| body mass) statistical difference between the trained and sedentary group for MCT1 and 
MCT4 protein concentration within the red and white gastrocnemius (Λ =0.924, 
p=0.508).  Body mass was an overall significant covariate for both MCT1 and MCT4 
within red and white gastrocnemius (Λ =0.611, p<0.01).  The significant effect of body 
mass was seen in the follow up ANCOVA for MCT4 in both red and white 
gastrocnemius (F=14.217, p<0.01, F=7.242, p=0.01 respectively).  Body mass was also 
significantly associated with MCT1 in red, but not white, gastrocnemius (F=18.266, 
p<0.01).  While there was a statistically significant difference between red and white 
gastrocnemius for MCT1 protein content across both groups (p<0.01), there was no 
significant effect of training between the groups (F=0.182, p=0.672) as shown in Figure 
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3.3.  There was no statistically significant difference in MCT1 in cardiac muscle between 
a sub-set of trained and a sub-set of sedentary rats (F=0.139, p=0.712) as seen in figure 3-
3.  However, there was a statistically significant difference between red gastrocnemius 
and white gastrocnemius for MCT1, and further significant difference between cardiac 
muscle and both red and white gastrocnemius (as shown in figure 3.4). 
 
 
 
 
Figure 3.3.  MCT Protein Content in Red and White Gastrocnemius and Cardiac  
 
Muscle between Trained and Sedentary Rats. 
 
 
There were no overall significant group differences (MCT1, MCT2, MCT4 = 
group | body mass) in MCTs within the VMH between the trained and sedentary group 
(Λ=0.955, p=0.579), and body mass was not a significant covariate (Λ=0.984, p=0.878) 
as shown in Figure 3.5.  There was no significant difference in follow up ANCOVAs in 
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MCT1, MCT2, or MCT4 in the VMH between exercise trained and sedentary animals 
(F=0.105, p=0.747, F=0.261, p= 0.612, and F=1.426, p=0.239 respectively). 
 
 
 
 
Figure 3.4.  MCT1 Protein content in Red and White Gastrocnemius 
 
 and Cardiac Muscle.  
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Figure 3.5.  MCT Protein Content within the VMH between 
 
Trained and Sedentary Rats. 
 
 
Discussion 
In the current study, 6-7 weeks of progressive exercise training in rats did not 
result in significant differences in MCTs within the VMH of exercise trained animals 
compared to sedentary animals.  These findings are congruent with those of Aveseh et al. 
0
1
2
3
4
5
6
7
8
9
10
MCT1 MCT2 MCT4
A
rb
it
ra
ry
 U
n
it
s
sedentary
trained
77 
 
(2014) who showed no changes in MCT1 or MCT2 in cerebral cortex, cerebellum, and 
hippocampus after 8 weeks of aerobic training 20.  The current study’s findings were in 
spite of strong evidence that aerobic adaptations had occurred, as determined by the 
increased cytochrome c oxidase activity in the trained group (figure 3.2).  This made the 
findings that skeletal muscle MCTs were not affected by training even more surprising, 
as Baker et al. (1998) had previously reported that skeletal muscle MCTs were increased 
after 1, 2, and 3 weeks of aerobic training 26.  Because of these discrepancies, the current 
study workloads were compared to previous work in an attempt to understand the 
increased training, but lack of increased MCT content. 
Exercise training has been shown in several studies to increase MCT content in 
skeletal and cardiac muscle, however no increases in MCTs were seen in either of these 
tissues in the current study 22,27,158.  The lack of increases in MCT protein content in 
brain, skeletal muscle, or cardiac muscle may be explained by the exercise intensity 
utilized in the current study.  Treadmill speed and grade were used to estimate a workload 
in METS (using 3.5ml/kg/min as the equivalent of 1 MET) to compare between previous 
studies using treadmill training in rats, as seen in figure 3.6.  The current study’s intensity 
was approximately 3.49 METs at the end of the 3-week ramping protocol and this 
intensity was maintained over the next 3-4 weeks.  A study by Baker et al. (1998) found 
that 2.46 METs was inadequate to increase MCT1 in red or white gastrocnemius over 3 
weeks of training 26,  but that approximately 4.29 METs would increase MCT1 in red, but 
not white  gastrocnemius 26.  The lack of change in cardiac MCT1 was also unexpected 
due to the same study detecting increased MCT1 in cardiac muscle using only 2.46 METs 
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over 3 weeks 26.  However, the current study did find the stepwise increase in MCT1 in 
increasingly oxidative muscle tissue (Figure 3.5), which has been shown by other studies 
114,136,157.   
 
 
 
Figure 3.6.  Comparison of Rat Treadmill Training Studies and MCTs in Muscles 
 
 by Daily Workload Expressed in MET Minutes/Day. 
 
 
Both Takimoto et al. (2014) and a more recent study have shown increased MCT 
expression in skeletal muscles after a single exercise bout 22.  A study by Coles et al 
(2004) showed an acute increase in MCT1 mRNA and protein in red and white 
gastrocnemius and MCT4 mRNA and protein only in red gastrocnemius using 
approximately 3.23 METs 22.  However, this acute study used an exhaustive exercise 
bout, and thus, a less intense effort may have been required to cause MCTs to be up-
regulated.  Although the METs in the study by Coles et al. (2004) were lower than in the 
current study, their longer duration translated to more MET minutes/day.   These results 
suggest that when designing exercise training protocols to investigate MCT changes, the 
important factor may be the overall workload of the exercise.  
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While intensity and duration seem to be important for MCT adaptations in 
skeletal and cardiac muscle, METs may not be the best metric for comparing protocols.  
METs are an absolute measure of intensity, and 2 individuals, of differing fitness levels, 
performing exercise at the same MET are working at different relative workloads.  
Considering the proposed and documented role(s) of MCTs in various tissues, it is 
reasonable to assume that exercise workloads that do not induce lactate production or that 
do not require the tissue to rely on an alternate fuel source, are not likely to stimulate 
changes in MCT protein content.  The lack of changes in MCTs within muscles between 
exercise trained and sedentary rats within the current study may have been due to early 
training adaptations that were lost after more robust training adaptations had occurred.  
Due to increases in cytochrome c oxidase activity, the muscles likely do not need to 
increase lactate shuttling, because it can more effectively perform oxidative metabolism 
and less lactate is produced.  Therefore, ever increasing workload (either by increasing 
intensity or duration or both), may be necessary to see sustained alterations in MCTs. 
While short-term training protocols in rats use a fixed workload, the rats’ relative 
workload over the course of the study changes as they adapt (ie, high percentage of 
capacity at the beginning and a lower percentage at the end).  It may be that the degree of 
physiologic overload is important to the expression of MCTs within skeletal and cardiac 
muscle 27.  For example, a study by Hoshino et al. (2014) showed that aerobic training 
supplemented with exogenous lactate produced greater increases in MCT1 than aerobic 
training alone 149.  Another study by Saxena et al. (2016) used rats to show  that hypoxia 
preconditioning with cobalt chloride (CoCl2) supplementation increased MCT1 in red 
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gastrocnemius significantly more than a group given distilled water 148.  In addition, a 
hypoxia preconditioned swim trained group increased MCT1 in red gastrocnemius to a 
greater extent than swim training alone 148.  This is in agreement with studies that have 
shown that HIF1α can stimulate MCT mRNA and protein, and suggests that higher 
intensity exercise, which increases lactate and causes hypoxia, may enhance MCT 
expression 151.  The current study may have elicited this response early in training (1-4 
weeks), but without continuing to increase the intensity of exercise, the adaptations may 
have been lost.  This “de-training” effect has been shown when hypoxia is removed from 
adipocyte cultures expressing MCTs 151. 
There are far fewer studies that have investigated MCT protein content in the 
brain in response to exercise, which makes the current results difficult to interpret.  The 
current study conflicts with one acute study by Takimoto et al. (2014), but is in 
agreement with a chronic training study by Aveseh et al. (2014).  There are several 
reasons that these discrepancies may have occurred.  First, it is possible that the increases 
in MCTs were present in the entire hypothalamus, as reported by Takimoto et al. (2014), 
but not to an appreciable degree within the specific region of the VMH.  Another 
possibility is that the increase in hypothalamic MCTs occurs on an acute basis only, but 
then returns to baseline as animals adapt to training.  In contrast, it is possible that the 
training protocol used in the current study was not of sufficient intensity to stimulate a 
response in the MCTs.  The study by Takimoto et al (2014) used only a single bout of 
exercise at 20m/min and 8% grade, an intensity that is lower than the current study 21.  
However, the single bout lasted for 120 minutes, twice as long as any single bout within 
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the current study’s training schedule, among naive rats 21.  When considering the overall 
workload, the Takimoto et al (2014) study provided a significantly greater acute stimulus 
than any single exercise session in our study. Lastly, it is possible that the antibodies used 
by Takimoto et al. were more sensitive to their respective MCT, and were therefore able 
to measure a change in MCT content that the current study could not.  
In addition to MCT protein content, a study by Aveseh et al. (2014) also 
examined the counter-regulatory response to hypoglycemia.  While exercise training has 
not been shown to cause a blunting of a subsequent counter-regulatory response to 
hypoglycemia, acute exercise has been shown to produce this response.  It is unknown 
whether acutely increased MCTs from exercise could contribute to this blunted response 
by allowing increased lactate shuttling to neurons, and preserving relative energy levels 
therein.  It is known that lactate administration within the VMH can cause a blunted 
response to hypoglycemia 24,25,90.  The study by Aveseh et al. (2014) showed a blunted 
counter-regulatory response to hypoglycemia only among the diabetic animals, regardless 
of training.  Both the trained and untrained (uncontrolled) diabetic animals had elevated 
MCTs within the brain, although their study did not measure MCTs within the 
hypothalamus 20.  It was also shown that the exercise trained animals and un-trained 
controls had a normal counter-regulatory response, and lower MCT content within the 
brain 20.  Therefore, MCTs and lactate may still be related to the antecedent exercise 
induced diminished response to subsequent hypoglycemia, but aerobic training does not 
seem to produce this effect. 
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It is of note that the total content of MCT protein does not indicate the activity of 
MCT proteins.  MCT protein content within the VMH may already be adequate to shuttle 
lactate or other monocarboxylates without having to increase transcription and translation 
to produce more transporters.  This is possible due to the fact that lactate shuttling should 
not be occurring under all conditions, but stimulated to occur by increased activity.  
Increased glutamatergic signaling leads to the stimulation of GluR on neurons which 
cause MCT2 to translocate to the cell surface.  At the same time, Na coupled glutamate 
uptake by synaptisomal projections on astrocytes leads to increased glycolytic rate to 
increase NaKATPase pumps.  Only under these high glycolytic conditions would the lower 
pH and increased lactate concentration overcome the km of MCT4 to export lactate.  
Because the lactate flux was not measured, it is unknown whether increased shuttling 
occurred during the current study.   
Besides the potential changes in flux versus content, MCT proteins may be 
affected by other monocarboxylates which they can transport.  The feeding protocol 
during the current study may have led to increased ketone body production in the animals 
during fasting conditions or after exercise.  It has been shown that Sprague Dawley rats 
become ketotic after a 24 hour fast, just 10 hours more than was used in the current study 
165.  This may have masked exercise induced changes in MCTs, due to the MCTs’ role in 
transporting ketone bodies into the brain.  However, overnight fasting combined with 
exercise leads to an exaggerated increase in ketone bodies post-exercise compared to 
overnight fasting and rest 166.  Therefore, the current study’s groups should still have been 
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affected differently if the MCTs were being influenced by ketone body production in 
addition to exercise induced lactate and hypoxia. 
A potential source of error when comparing the findings of the current study to 
other studies are the antibodies and procedures used for western blotting and quantifying 
data.  The current study used commercially available antibodies for MCT1, MCT2, and 
MCT4; while most other studies use antibodies generated in their own lab.  This makes 
data replication difficult, if not impossible, because other labs do not have access to the 
same materials.  While all antibodies should specifically bind their target (MCT1, 2, or 4) 
there is marked differences in different antibodies 136.  This is particularly true for band 
intensity, which is used to quantify protein data via densitometry.  In addition, different 
densitometry methods can be used which would affect the quantities obtained.  However, 
the current procedures were able to measure differences in different muscle and cardiac 
tissue types (more or less oxidative) and changes up to 10-20% in controlled tests.  
Therefore, if the current study samples were analyzed with different methodology, slight 
differences may be expected, however, no differences between groups would likely be 
observed. 
In summary, the data from the current study partially supports the findings of 
Aveseh et al. (2014) 20.  The findings by Takimoto et al. (2014), while not a training 
study, indicated increased MCTs in the hypothalamus 5 hours after an exercise bout 21.  
Although the current study took brain samples approximately 5 hours post-exercise, no 
increase was apparent.  This may indicate that MCT changes may occur acutely and 
eventually return to baseline.  Future studies should attempt to determine whether acute 
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exercise increases MCT protein content within the VMH.  In addition, rats that have 
acutely exercised (within 24 hours) should be given a hypoglycemic challenge to confirm 
that the antecedent exercise induced HAAF response is consistent in rats as it is in 
humans.  Independent MCT inhibitors (such as oligodeoxynucleotides, or shRNAs) could 
be used to block specific MCTs to determine whether their removal corrects the HAAF 
response rather than using 4CIN, which is a less specific inhibitor.  The VMH may also 
be tested after an animal is exposed to hypoxia or CoCl2 to determine if VMH MCTs are 
responsive to HIF1α as in other tissues, and whether this produces a HAAF response. 
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CHAPTER IV 
 
RECURRENT HYPOGLYCEMIA, LEADING TO HYPOGLYCEMIA ASSOCIATED 
AUTONOMIC FAILURE, DOES NOT ALTER MCT CONTENT WITHIN THE 
VENTROMEDIAL HYPOTHALAMUS OF RATS 
 
 
Abstract 
An increasing number of Americans suffer from diabetes mellitus, which leads to 
several diabetic health complications if blood glucose is not properly managed.  The 
Diabetes Complications and Control Trial showed that tightly controlling blood glucose 
concentrations through aggressive medication can prevent several diabetic complications, 
however it also leads to increased incidences of hypoglycemia.  If two hypoglycemic 
incidents occur in relatively short succession (24 hours) the second instance is likely to 
have a diminished hormonal response to correct the hypoglycemia.  In addition, the 
deeper the antecedent hypoglycemia, the more severe the suppression of the subsequent 
counter-regulatory response.  This can lead to a downward spiral of ever worsening 
hypoglycemia among individuals with insulin dependent diabetes.  The loss of 
responsiveness to repeated episodes of hypoglycemia has been hypothesized to be related 
to changes in energy substrate utilization by neurons within the ventromedial 
hypothalamus.  In particular, glial cells may use monocarboxylate transport proteins to 
shuttle lactate to neurons to supply them with energy when deprived of glucose.  
Therefore, the objective of the current study was to determine whether recurrent 
antecedent hypoglycemia leads to changes in monocarboxylate transport proteins within 
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the ventromedial hypothalamus.  It was hypothesized that the monocarboxylate transport 
proteins would be increased by recurrent antecedent hypoglycemia.  To determine 
whether monocarboxylate transport proteins change, male Sprague-Dawley rats were 
given subcutaneous injections of either insulin (RH) or saline (C) on 3 consecutive days 
before having their ventromedial hypothalamus removed.  A subset of these animals from 
both groups were given a hypoglycemia challenge on day 4 and had blood samples taken 
at 0, 15, 30, 60, 90, and 120 minutes post insulin injection.  These blood samples were 
analyzed for counter-regulatory hormones (glucagon, epinephrine, and norepinephrine), 
to assess whether the RH was sufficient to suppress the counter-regulatory response.  It 
was shown that despite 3 days of recurrent hypoglycemia, there were no changes in the 
monocarboxylate transport proteins within the ventromedial hypothalamus.  There was 
no significant difference in glucagon response among the subsets of rats on day 4, 
although there was a significantly lower glucose AUC for the RH group.  Because there 
were no changes in monocarboxylate transport proteins after recurrent hypoglycemia, it 
seems unlikely that these transport proteins are required to change in order to suppress 
the counter-regulatory response to hypoglycemia. 
Introduction 
While many organs in the body contribute to glucose homeostasis, the central 
nervous system is integral to proper responses to hyperglycemia and hypoglycemia 
30,68,84,88.  However, hypoglycemia poses an acute health risk, particularly for individuals 
with insulin dependent diabetes mellitus (IDDM) 12,15,70.  Severe hypoglycemia can lead 
to increased macro and micro vascular events as well as cardiovascular dysrhythmias and 
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death 70,167.  In addition to the acute risks of hypoglycemia, each hypoglycemic episode 
seems to reduce the responsiveness to a subsequent hypoglycemic episode 12,13,70,78.  The 
risk of subsequent reduced responsiveness seems to be related to the depth of the 
subsequent hypoglycemia rather than the duration 66,69.  This phenomenon has been 
referred to as hypoglycemia associated autonomic failure, or dysfunction, (HAAF) which 
can develop into a dangerous cycle of recurrent hypoglycemia 15. 
While several brain areas have been identified as important to this process, there 
has been particular interest in studying the ventromedial hypothalamus (VMH) 25,30,67.  
The VMH coordinates the response to hypoglycemia, however the exact mechanisms are 
currently unknown 30.  When the VMH is treated with 2deoxyglucose (2DG) to induce 
glucoprivic conditions locally, there is a systemic counter-regulatory response to increase 
blood glucose concentrations 82,168.  In contrast, a counter-regulatory response to systemic 
insulin induced hypoglycemia can be attenuated with local administration of glucose into 
the VMH 169.  Therefore, the VMH seems to respond to local glucose concentrations to 
regulate systemic glucose concentrations via sympathetic efferents 30,67,87,100 
Although the VMH responds to glucose concentrations, the response may not be 
specific to glucose.  It has been shown that administration of lactate, rather than glucose, 
can lead to similar attenuation of the counter-regulatory response to systemic insulin 
induced hypoglycemia 24,25,90.  This is most likely due to the energy state of the neurons 
within the VMH, which can take up lactate via monocarboxylate transport proteins 
(MCTs) to be used for oxidative phosphorylation 30,87,88,90,93,170,171.  The sensing of the 
energy state could be mediated through KATP channels similar to pancreatic β–cells 
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87,88,171.  Indeed, both neurons and glial cells express various MCTs which have different 
affinities for lactate and other monocarboxylates, which may favor lactate uptake by 
neurons. 
The expression pattern of MCTs, as well as other metabolic enzymes, within the 
brain has led to the hypothesis that glycolysis or glycogenolysis derived lactate can be 
shuttled from astrocytes to neurons to support oxidative phosphorylation 113,133,162.  This 
model has become known as the astrocyte to neuron lactate shuttle hypothesis (ANLS).  
The ANLS model has been used to explain how neurons co-cultured with glycogen rich 
astrocytes can be stimulated longer than those co-cultured with glycogen depleted 
astrocytes, or how neuronal activity during hypoglycemia can be maintained in the 
presence of lactate 23,28,120,123,133,162.  This may mimic the glycogen depletion during 
hypoglycemia and the super-compensation that follows 109,111,112.  In addition others have 
recently reported that recurrent antecedent hypoglycemia can lead to enhanced lactate 
transport in the brain compared to control animals 23.  However, no measurement of 
lactate transporters or lactate-related metabolic enzymes were measured.  It is, therefore, 
of interest to know whether lactate is shuttled to neurons from blood glucose or from 
astrocytic glycogen, leading to an attenuated counter-regulatory response to 
hypoglycemia after antecedent recurrent hypoglycemia. 
To approach this question, the current study measured changes in the different 
MCTs (1, 2, and 4) within the VMH in response to 3 consecutive days of systemic insulin 
induced hypoglycemia.  While this study was not able to quantify the actual lactate flux 
between astrocytes and neurons, total changes in MCT proteins were assessed.  
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Additionally, HAAF response was confirmed through hormonal changes throughout a 
hypoglycemic challenge.  It was hypothesized that recurrent hypoglycemia would lead to 
increases in MCT2 and MCT4 to facilitate increased lactate shuttling from astrocytes to 
neurons. 
Methods 
All rats were received from Charles River and allowed to acclimate to the animal 
facility for one week before any hypoglycemia or surgeries began.  Male Sprague Dawley 
rats were individually housed in shoebox cages on a 12 hour light / dark cycle and given 
ad libitum access to food and water 24 hours a day, except during hypoglycemia 
exposures and blood sampling.  All rats received 3 days of either hypoglycemia or 
vehicle (saline), while a sub-group of rats were given a 4th day of hypoglycemia to 
measure blood glucose and hormone response. 
Surgeries;  A sub-group of rats had a jugular vein catheter surgically installed 
before beginning their 3 days of hypoglycemia (Appendix C).  The procedure, briefly, 
entailed making a small incision in the chest to insert a catheter into the right jugular 
vein.  Then a port was fixed to the top of the skull to allow access for blood sampling, 
and to avoid the rat damaging the port.  After surgeries, the rats were moved to tall cages 
and allowed to recover for 3 days before beginning the hypoglycemia treatments. 
Hypoglycemia;  After the rats had acclimated to the animal facility, they were 
subjected to either hypoglycemia or sham treatment for 3 consecutive days.  Midway 
through the light cycle the food was removed from the rats’ cages.  They were weighed 
and then given a subcutaneous injection of either insulin or saline at a dose of 4.5U/kg or 
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0.45ml/kg, respectively.  The rats were then replaced in their cages and observed to 
ensure that no severe reactions occurred.  After 30 minutes, the rats were removed from 
their cages and a small amount of blood was acquired through a pedal vein stick.  In the 
sub-group of rats with jugular vein catheters, the catheter was used to collect blood 
samples 30 minutes after the injection.  The blood was used to measure blood glucose 
concentration at 30 minute post-injection using an AccuChek Glucometer (ACCU-CHEK 
Aviva Plus, Roche Diabetes Care, Inc., Indianapolis, IN).  After hypoglycemia was 
confirmed, food was replaced in the rats’ cages.  This procedure was repeated for 3 
consecutive days.  After 3 days of hypoglycemia, the rats were sacrificed on day 4, 24 
hours after the last hypoglycemia. 
Blood Sampling;  After 3 days of hypoglycemia or sham, a sub-group of rats from 
each group were given an injection of insulin, regardless of their previous group, to 
produce hypoglycemia, and measure hormonal response (Appendix D).  A length of 
tubing was attached to the catheter port fifteen minutes before blood sampling began to 
avoid measuring hormonal responses to handling.  The hypoglycemia was achieved as 
previously described using insulin injections in both the previously hypoglycemia and 
previously sham animals.  Blood samples were taken from the catheter without touching 
or handling the animal at time points: -10min, 0min, 15min, 30min, 60min, 90min, and 
120 min relative to the injection at time zero.  Animals were handled after time point 
0min to administer insulin injections.  Blood samples were heparinized and centrifuged 
immediately and plasma was stored with protease inhibitors and immediately frozen.  
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Once 2 hour blood sampling was completed, the rats were sacrificed via CO2 chamber 
and decapitation. 
Western Blot Procedures;  After rats were sacrificed, their brains were removed, 
and the VMH was collected and immediately frozen.  The VMH was homogenized with a 
glass mortar and pestle on ice using a RIPA buffer (Appendix A).  Protease inhibitors as 
well as phosphorylase inhibitors were also added to prevent any degradations or 
alterations of proteins in the lysate.  After homogenization, the samples were sonicated 3 
times each to disrupt any cell membranes.  The samples were centrifuged for 15 minutes 
at 14,000 RPM (18,407 RCF) afterward, supernatants were collected and stored at -80°C.  
A BCA assay (Pierce BCA Protein Assay Kit) was used to assess the total protein content 
within each sample.  When running the western blotting assays, 20µg of total protein was 
added to each lane.  Electrophoresis was run overnight at 60 volts.  Proteins were 
transferred to PVDF membranes over 6 hours at 200 milliamps. 
Samples were run for MCT1, MCT2, and MCT4 using primary antibodies 
purchased from Santa Cruz Biotechnology (sc-50325, sc-50323, and sc-50329 
respectively).  Antibodies were applied in 5% milk at 1:200 for MCT1, 1:250 for MCT2, 
and 1:100 for MCT4 on a rocker overnight in a 4°C cooler.  Secondary antibody for anti-
rabbit (Pierce 31460) was applied in 5% milk at 1:5000 on a rocker for 2 hours at room 
temperature.  Blots for VMH were exposed in a BioRad Chemidoc station for 140 
seconds for MCT1, 200 seconds for MCT2, and 300 seconds for MCT4.  After initial 
exposure, PVDF membranes were stripped and probed with primary antibody for 
GAPDH (sc-166545).  Antibody was applied in 5% milk at 1:4000 on a rocker overnight 
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in 4°C cooler.  Secondary antibody for anti-mouse (Pierce 31450) was applied in 5% 
milk at1:2000 on a rocker for 2 hours at room temperature.  Blots for GAPDH were 
exposed in a BioRad Chemidoc station for 40 seconds.   
Band intensities from western blots were quantified using densitometry tools on 
Quality One software.  All densitometry was performed by the same researcher in the 
same manner, and without knowledge of treatments per lane.  A ratio of MCT to GAPDH 
was determined, and a natural log transformation was used to normalize all data, to 
account for non-normal distribution of ratio data.  Further description of western blotting 
procedure can be found in appendix B. 
Hormones; Glucagon was determined using Mercodia glucagon ELISA (10-1281-
01, Mercodia Developing diagnostics, Uppsala, Sweden).  Briefly, 10µl of calibrators and 
samples were added to a 96 well plate.  Then, 50µl of enzyme conjugate was added and 
the plate was incubated on a plate shaker at 800rpm overnight in a 4°C cooler.  The next 
day, the plate was removed and washed 6 times on an automatic plate washer.  Then 
200µl of TMB substrate was added to each well and the plate was incubated for 30 
minutes before adding 50µl of stop solution.  The plate was briefly shaken to ensure 
mixing, and read on a Gen5 plate reader at 450nm. 
Statistics; All statistics were run using SPSS version 23 (IBM, Armonk, New 
York).  MANOVAs were run for MCT1, 2 and 4 for recurrently hypoglycemic and 
control rats using body mass as a covariate.  A MANOVA was also run for percent 
MCT1, 2, and 4 compared to control mean for recurrently hypoglycemic and control 
animals using body mass as a covariate.  A repeated measures ANOVA was run for the 3 
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days of blood glucose monitoring using an independent T-test as a follow up to compare 
each day.  A one way ANOVA was used to compare blood glucose concentration area 
under the curve for they hypoglycemic challenge and for body mass.   
Results  
Subcutaneous injections of insulin were sufficient to produce a significant 
reduction in blood glucose concentrations 30 minutes post injection compared to the 
group receiving saline injections (F=385.11, p<0.01) as shown in Figure 4-1.  There was 
no significant within group variance for blood glucose concentrations 30 minutes post 
injection (F=2.23, p=0.12).  Indeed, the subset of rats that were sampled for confirmation 
of HAAF response showed statistically significant reduction in blood glucose area under 
the curve (AUC) over the hypoglycemic challenge (F=10.57, p=0.04) as shown in Figure 
4.2.  However, there was no significant difference in blood glucose concentration 
between groups for the repeated measures ANOVA (F=5.432, p=0.1) as seen in figure 
4.3A.  There was no significant difference in glucagon between groups in the repeated 
measures ANOVA (F=0.248, p=0.65), however, both the control group and RH group 
seemed to have a blunted glucagon response seen in figure 4.3B compared with other 
studies measuring the HAAF response.  There was also no significant difference in 
glucagon AUC between groups (F=0.21, p=0.68).   
There was no statistical difference in body mass between the two groups 
(Control=351.1g ± 28.6, RH=333.8g ± 28.7; F=0.18, p=0.67), however, there was a large 
range of body mass within each group. 
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Figure 4.1.  Thirty Minute Post-Injection between Control and RH Rats 
 
over 3 Days 
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Figure 4.2.  Glucose AUC for Subset of Blood Sampled Rats During  
 
Hypoglycemic Challenge. (* indicates p<0.05)  
 
 
 
 
Figure 4.3.  The Blood Glucose and Glucagon During the 
 
Hypoglycemic Challenge 
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There was no statistically significant difference in MCTs between recurrently 
hypoglycemic rats and control rats (Λ=0.993, p=0.95) as shown in Figure 4.4.  However, 
there was a statistically significant difference in MCTs across different body mass 
(Λ=0.617, p<0.01).  Follow up ANOVAs showed that there was a statistically significant 
effect of body mass for MCT1 (F=22.23, p<0.01), MCT2 (F=6.08, p=0.02), and MCT4 
(F=15.00, p<0.01) as seen in Figure 4.5.  As shown by the F statistic, the majority of 
variance accounted for by body mass is within MCT1 concentrations. This is also visible 
when the body mass and MCT concentrations are plotted out, as seen in Figure 4.5. 
 
 
 
Figure 4.4.  The MCT Protein Content within the VMH 
 
between RH and Control Rats. 
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Figure 4.5.  The Comparison of Body Mass and MCT Protein Content. 
 
 
There was also no significant change in MCTs for recurrently hypoglycemic 
animals as a percent of the average control animal MCT content (Λ=0.98, p=0.86) as 
seen in Figure 4-6.  However, body mass was still significant for percent of average 
control animal MCT content (Λ=0.68, p<0.01).  Again, all follow up ANOVAs showed 
significant difference in percent of MCT1 (F=7.36, p=0.01), MCT2 (F=6.44, p=0.01), 
and MCT4 (F=16.44, p<0.01) across body masses. 
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Figure 4.6.  The MCT Percentage within the VMH between 
 
  RH and Control Rats. 
 
 
Discussion 
Recurrent hypoglycemia leading to a HAAF response did not lead to changes in 
the overall protein content of any of the predominant MCTs within the VMH.  Although 
it cannot be determined whether there was increased shuttling through the MCTs during 
the hypoglycemic episodes, there seemed to be no need for the cells to produce additional 
transport proteins.  This finding does not confirm or deny the ANLS hypothesis.  
However, it seems that the lactate shuttling (if it occurs) does not require an increases in 
transport proteins in the VMH to cause a HAAF response to antecedent recurrent 
hypoglycemia.  This may be because, under basal conditions, lactate concentrations do 
not overcome the high km of MCT4 in astrocytes.  The lactate shuttling, if it occurs, 
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would only be under conditions of high glycolytic rates within astrocytes, potentially 
driven by increase glutamate and sodium uptake increasing Na/KATPase pumps. 
It was reported by Herzog et al. (2013), that rats exposed to 3 days of antecedent 
recurrent hypoglycemia experienced a 2 fold increase in lactate transport in the brain 
during a fourth episode of hypoglycemia on the 4th day 23.  In addition, they showed that 
lactate infusion could rescue reduced brain activation during hypoglycemia in rats given 
antecedent recurrent hypoglycemia, but not control rats 23.  This seemed to suggest that 
the recurrently hypoglycemic rats had increased lactate uptake and/or metabolism 
compared to control animals as an adaptive response to recurrent episodes of 
hypoglycemia.  However, there was no investigation of MCT mRNA or protein content.  
Despite these findings, the current study seems to suggest that, if these adaptations occur 
with antecedent recurrent hypoglycemia, this is more likely caused by changes in 
metabolic enzymes rather than MCT protein content. 
It is possible that insulin induced hypoglycemia acutely affects MCT content, but 
then returns to basal levels 137.  It has been suggested that MCT2 expression was 
increased in neuronal cell culture when exposed to 1µg/ml insulin for 2 to 8 hours, but 
was not increased after 24 hours 137.  The authors measured mRNA and saw no changes, 
and concluded that MCT2 is regulated at the translational level 137.  However, the study 
involved insulin injections directly into the brain, rather than delivered systemically as 
with a hyperinulinemic hypoglycemic clamp, or normal insulin use by individuals with 
IDDM.  Usually, insulin concentrations in plasma are about 10-20 fold higher than in 
cerebrospinal fluid (CSF) 172.  Insulin delivery to the brain seems to be saturable and, 
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regardless of insulin infusion rate, CSF insulin only reaches around 4µU/ml 173.  It is also 
possible that glucose sensing neurons within the VMH are responsive to insulin 170. 
A recent study by Aveseh et al. (2014) did show increased MCT protein content 
within certain brain regions in diabetic animals compared to their healthy controls 20.  
These animals showed a HAAF response to insulin induced hypoglycemia regardless of 
whether or not they were aerobically exercise trained.  This suggested that the increased 
brain MCTs may play a role.  However, MCTs within the hypothalamus were not 
measured, although the hypothalamus is known to be intimately related to the counter-
regulatory response to hypoglycemia.  In addition, the rats in their study were made 
diabetic through streptozotocin (STZ), which leads to chronic hyperglycemia 141.  It has 
been shown that STZ induced hyperglycemia can induce increases in MCT1 in many 
brain regions, including the hypothalamus 141,142,174.  Our current study showed no 
relationship between MCTs and a HAAF response induced with antecedent recurrent 
hypoglycemia.  However, because our animals were not STZ treated, they never 
experienced the chronic hyperglycemia which may explain the differences in the MCTs 
in the Aveseh et al (2014) study. 
The current study did show a strong relationship between body mass and the 
amount of MCT1, 2, and 4 proteins in the VMH.  It is unknown what factors are affecting 
this relationship.  MCT1 seemed to be positively associated with increased body mass, 
while MCT2 and MCT4 did not have as clear of an association.  MCT1 has been 
previously shown to be associated with body mass as well as hyperglycemia 141,142,175.  
However, it seems less likely that MCT1 causes these changes, and rather, that it is 
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responding to them.  Other studies have shown that MCT1 content within the VMH and 
arcuate nucleus may play a role in feeding behaviors being regulated by multiple energy 
substrates including ketone bodies 142,153-156,175.  Therefore, the relationship between 
MCT1 and body mass may be regulated through many circulating substances that change 
as the body increases or decreases fat or lean mass.  The use of rats of varying weights 
and ages may have led to increased variance in MCTs which was accounted for by the 
differences in body mass. 
Due to the timing of sacrifices, some changes in protein content may have been 
missed.  We would not have necessarily detected changes in protein levels if they 
occurred acutely after hypoglycemia.  However, the HAAF response has been shown to 
be present 24 hours after an antecedent hypoglycemic event.  Therefore, even if MCTs 
were only acutely changed, the fact that there were no significant differences in MCTs at 
24 hours post-hypoglycemia suggests that they are not strongly related to the HAAF 
response.  Another potential limitation was the depth of hypoglycemia which was 
achieved with the current study’s protocol.  While subcutaneous insulin injections are the 
most common route of administration in individuals with IDDM, the depth and duration 
of hypoglycemia achieved is not as precise as a hyperinsulinemic hypoglycemic clamp.  
Therefore, the exact glycemia of the rats throughout the study was not entirely uniform, 
and the same was true for the comparison between recurrently hypoglycemic and naive 
rats during hypoglycemia.  While the current study achieved mild hypoglycemia, the 
HAAF response is associated with depth of hypoglycemia, and may not have been 
triggered.   
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Recurrent hypoglycemia and the associated hypoglycemia associated autonomic 
failure create a real problem for individuals with IDDM who must choose between long 
term benefits and short term risks.  The changes which cause this dysfunction within the 
VMH are still unknown, however, it seems unlikely that they are mediated by changes in 
the MCT protein contents within this brain area.  Lactate shuttling and ANLS may still 
play a role in HAAF, but the transport proteins are not required to change.  Therefore, 
other components of the ANLS may warrant investigation. 
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CHAPTER V 
 
OVERALL DISCUSSION 
 
 
There are two common methods by which a hypoglycemia associated autonomic 
failure (HAAF) is likely to occur, antecedent exercise or antecedent hypoglycemia 
12,13,15,17-19,66,78.  Insulin use by individuals with insulin dependent diabetes mellitus 
(IDDM) can cause antecedent hypoglycemia 16,64.  In addition, exercise in individuals 
with IDDM may itself cause hypoglycemia immediately, or delayed by several hours 
57,63.  However, both of these treatments are widely recommended to control high blood 
glucose concentrations as well as to reduce the risk of diabetic complications 16,57,58,63.  
Therefore, it is important to understand why these two common tools for diabetes 
treatment can become detrimental under certain circumstances, particularly when an 
individual with IDDM enters a cycle of hypoglycemia and HAAF 12,15,70.  Both of these 
treatment methods have been extensively studied in terms of their ability to cause a 
HAAF response, however, few attempts have been made to determine any common 
mechanisms.  By examining both methods of inducing HAAF, new mechanisms of action 
may be understood.  Once the underlying mechanisms are understood, steps can be taken 
to find a way to treat or prevent the HAAF response, allowing tighter regulation of blood 
glucose concentrations in individuals with diabetes mellitus. 
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The central purpose of these studies was to better understand the role of MCTs in 
the HAAF response from either antecedent exercise or antecedent hypoglycemia.  It has 
been suggested that exercise can increase MCTs within the brain, and specifically, within 
the hypothalamus 21.  Additionally, there are suggestions that there are changes in lactate 
handling in the brain after antecedent recurrent hypoglycemia 23.  Furthermore, lactate 
injection or infusion into the brain has been used to induce a HAAF response, despite 
systemic hypoglycemia.  However the concentrations used in most studies were greater 
than what would be present under normal physiologic conditions 24,25.  Studies using 
more physiologic concentrations of lactate show similar findings, although they were 
performed in brain slices rather than in a live animal 90.  The mechanisms of how lactate 
would increase in the brain during hypoglycemia following antecedent hypoglycemia or 
exercise is unknown.  The most prevalent hypothesis is that there is a super-compensation 
of astrocytic glycogen that can be used for energy during the subsequent episode of 
glucoprivation 28,107-109,111,120. 
It has been shown that lactate as well as ketone bodies (and possibly short and 
medium chain fatty acids) can elicit responses from either “glucose exited” or “glucose 
inhibited” neurons within the VMH 90,153,154.  In addition, these “glucose sensing” 
neurons have been shown to possess the enzymes necessary for an astrocyte to neuron 
lactate shuttle (ANLS) 170.  The MCTs are present within these neurons, although few 
studies have attempted to link them to a HAAF response 24,170.  The current 2 studies, 
taken together, suggest that, whether or not lactate or ANLS is involved in the HAAF 
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response, there are no changes in MCT content in the VMH in response to either 
antecedent recurrent hypoglycemia or chronic aerobic exercise training.   
The current findings may be in line with other studies which have concluded that 
MCTs are not of particular importance for glucose sensing neurons in the hypothalamus 
170.  A study by Kang et al. (2004) sought to characterize the glucose sensing neurons 
within the VMH by mRNA expression patterns 170.  While they measured MCT mRNA 
in most neurons, there was no difference between glucose inhibited neurons, glucose 
excited neurons, or non-glucose sensing neurons 170.  In addition, they found that most 
neurons, regardless of type, expressed both LDH1 and LDH5, indicating that most 
neurons can take up lactate and convert it to pyruvate for oxidative phosphorylation.  
This is in line with the ANLS, however, it appears that this would occur no differently 
between glucose sensing neurons and other neurons 170.  However, this study should be 
interpreted with caution because they used relatively young rats, and it is known that 
MCT expression changes with development 170,176.  It has also been suggested that MCTs 
are regulated translationally rather than transcriptionally 137.  Regardless, the current 2 
studies have measured no changes in actual protein content of MCT’s regardless of the 
level of transcription or translation.  Therefore, it seems likely that MCTs or ANLS are 
not playing any larger role in the VMH and HAAF response to the metabolic processes of 
most other neurons in the brain. 
Interestingly, the study by Kang et al. (2004) found that there was significantly 
more insulin receptor mRNA in glucose sensing neurons compared to non-glucose 
sensing neurons, suggesting that brain insulin may be partially regulating the activity of 
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these neurons 170.  Additionally, a study by Chenal et al (2008) which suggested MCT2 is 
regulated translationally, showed that insulin administration increased MCT2 protein 
expression 137.  The role of insulin signaling in the brain playing a role in circulating 
nutrient homeostasis has been suggested by experimental studies which have shown 
intranasal insulin to affect hepatic glucose output regardless of peripheral insulin 
concentrations 177. Indeed, intranasal insulin has also been shown to have an effect on the 
regulation of triglyceride export from the liver 178.  In addition, the arcuate nucleus, 
which is in direct contact with the ventromedial nucleus (both within the VMH) has been 
shown to be affected by different hormones and nutrients to influence feeding behaviors 
153,155,156,174,179.  Taken together this seems to suggest that the VMH is playing a larger 
role in metabolic sensing and regulation beyond simply glucose, and that MCTs may 
have an important role in the arcuate nucleus as well as ependymal cells of the median 
eminence.  
There are three major points to be taken from the current studies: 1) the current 
findings neither confirm nor contradict an ANLS occurring within the VMH, 2) the 
current study does not confirm nor contradict a model that suggests increased lactate use 
by neurons in the VMH during hypoglycemia, but 3) the current study does show that 
whatever changes occur to produce a HAAF response, they are independent of changes in 
the MCT protein concentration which shuttle lactate.   
Because all of the MCT isoforms were detected in varying amounts within the 
VMH, it is still physiologically possible for an ANLS to occur in this region.  In addition 
the findings of previous researchers that indicate either changes in lactate flux in the 
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brain, or the ability of lactate to induce a HAAF response, may still be valid 23,24.  It is 
possible that MCT content is already sufficient to shuttle lactate at rates higher than 
observed under basal conditions.  This is due to the high km of MCT4 which should not 
export lactate unless glycolytic rate increases.  It is also possible that there are changes 
that occur in astrocytic glycogen, lactate metabolism, or oxidative enzymes rather than 
changes in MCT protein concentration 107,111,128.  Both exercise and hypoglycemia have 
been shown to deplete brain glycogen and induce subsequent super-compensation in 
different brain regions 108,111.  Although these points have not been confirmed or refuted 
by the current studies, the absence of any differences in MCTs 24 hours after antecedent 
recurrent hypoglycemia confirms that the HAAF response is not contingent on increases 
in MCT protein content.  The HAAF response was measured, after antecedent recurrent 
hypoglycemia in the current study, and has been well documented after antecedent 
exercise in the literature 12,17-19,80.  If no change in MCT content is present within the 
VMH 24 hours post exercise or antecedent recurrent hypoglycemia, it can be concluded 
that their content does not have to change to induce a HAAF response which is present 
within this 24 hour window. 
Further studies will be needed to determine whether lactate flux or lactate 
metabolizing enzymes are changed by either antecedent exercise or antecedent recurrent 
hypoglycemia.  This could be accomplished by a specific knock down of astrocytic or 
neuronal MCT expression.  Then interstitial lactate concentrations could be measured by 
microdialysis.  If astrocytic MCT-KD or neuronal MCT-KD does not lead to decreased or 
increased (respectively) interstitial lactate concentrations, then it is unlikely that the 
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ANLS is occurring within the VMH.  Furthermore, super compensation of astrocytic 
glycogen leading to ATP maintenance in neurons would not be related to the HAAF 
response observed after either antecedent exercise or antecedent recurrent hypoglycemia.  
This is because astrocytes lack glucose 6 phosphatase to allow glycogen derived glucose 
to leave the cell.  Astrocytic glycogen can only provide fuel to neurons via other 
metabolic intermediates, such as lactate.  If this were the case, then increased activity of 
GABAergic neurons due to increased lactate flux leading to increased ATP:ADP ratio 
and stimulation of KATP channels would seem less likely in mediating the HAAF 
response 24,30. 
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APPENDIX A 
 
CHEMICALS 
 
 
Tris (pH 8.8)- 
 90.85g Tris Base 
 17ml HCl 
 In 500ml deionized water pH 8.8 
Tris (pH 6.8)- 
 30.3g Tris Base 
 20ml HCl 
 In 250ml deionized water pH 6.8 
APS (10%)- 
 4g Ammonium Persulfate 
 In 40 ml of deionized water 
2x Loading Buffer- 
 25ml Tris 6.8 
 40ml SDS (4%) 
 10ml glycerol (10%) 
  8mg bromophenol blue (0.008%) 
 Makes 100ml 
Electrophoresis buffer (10x)- 
   90.8g Tris Base 
 432.4g glycine 
      30g SDS 
 In 3 liters deionized water 
Transfer buffer (10x)- 
   90.8g Tris Base 
 432.4g Glycine 
 20% methanol 
 Makes 3 liters 
DTT- 
 154mg Dithiothreitol 
 In 10ml of deionized water 
10x TBST – 
   24g Tris Base 
   88g NaCl 
 10ml Tween 20x 
 In 1000ml deionized water pH 7.6 
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Stripping buffer – 
   15g Glycine 
     1g SDS 
 10ml Tween 20x 
 In 1000ml deionized water pH 2.2 
RIPA buffer –  
   50mM Tris Base 
     1mM EDTA 
 150mM NaCl 
        1% NP-40 
        1% Na Deoxycholate 
        1% SDS 
Phosphatase inhibitor – 
  4.3mg NaF 
 43.2mg β-Glycerophosphate 
 In 1ml RIPA buffer 
Catecholamine Extraction (CE) Tris Buffer- 
45g Tris Base  
5g Na2EDTA 
In 250ml deionized water pH to 8.6 with phosphoric acid. 
HPLC Mobile Phase- 
10.35g NaH2PO4•H2O   
0.389g 1-Octanesulfonic Acid  
  0.009g Na EDTA   
100ul   Diethylamine (DEA)     
70mL   Acetonitrile (ACN)   
In 1 liter of deionized water pH to 3.0 with phosphoric acid.  
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APPENDIX B 
WESTERN BLOTTING 
 
 
Sample preparation and Gel Electrophoresis 
For determination of protein content of samples, a western blotting analysis was 
used.  First a 12% acrylamide resolving gel was made for the gel electrophoresis.  The 
12% acrylamide gel consists of: 9.9ml of DI water, 12ml Acrylamide, 7.5ml Tris (pH 
8.8), 300μl of SDS (10%), 300μl of APS, and 25μl of TEMED.  This solution was poured 
into a cartridge to polymerize and capped with deionized water.  Electrophoresis buffer 
was made from 100ml of 10x electrophoresis buffer and 900ml of deionized water.  
Electrophoresis buffer was placed in the bottom tank of the Hoeffer SE400 vertical 
electrophoresis unit.  When resolving gel had polymerized, water cap was poured off, and 
the cartridge was gently dried with filter paper.  The cartridge was placed the tank 
containing electrophoresis buffer. 
A stacking gel was made and poured into the cartridge above the 12% resolving 
gel for the loading of the samples.  The stacking gel consisted of: 6.8ml of DI water, 
1.7ml of acrylamide, 1.25ml of Tris (pH 6.8), 100μl of SDS, 100μl of APS, and 15μl of 
TEMED.  The stacking gel was poured into the cartridge above the resolving gel once the 
deionized water is removed.  A comb is cleaned with 70% ethanol and dried before being 
inserted in the top of the cartridge to form the loading lanes.  The stacking gel was then 
allowed to polymerize. 
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All samples were measured out by total protein and combined with an equal 
amount of 2x loading buffer and DTT.  After loading, samples were gently vortexed to 
ensure mixing.  All samples were kept on ice until they were loaded into the gel for 
electrophoresis.  Before gel loading, all samples were briefly centrifuged to ensure all 
sample was at the bottom of the conical tube.  Once the stacking buffer had polymerized, 
the comb was gently removed, and lanes were straitened (if necessary).  Electrophoresis 
buffer was used to fill the lanes as well as to remove any bubbles.  The samples were then 
pipetted into appropriate lanes.  The Hoeffer SE400 electrophoresis top tank was then 
secured to the top of the cartridge.  The electrophoresis buffer was added to a top and 
bottom tank for the vertical electrophoresis chamber (SE400 Air-Cooled Vertical 
Electrophoresis Unit, Hoefer, Inc. Holliston, MA) and the gel electrophoresis was run 
over night (approximately 15-16 hours) at 60 volts.   
Transfer Electrophoresis 
Once the electrophoresis has run, the gels were carefully removed from its 
cartridge.  The stacking buffer was cut away, and any resolving buffer below the 
migration of the dye front was also removed.  The gel was then placed in transfer buffer, 
sandwiched between 2 sponges, 2 pieces of filter paper, and flush against a piece of 
polyvinylidene fluoride (PVDF) membrane as shown in figure B.1.  Together this was 
secured into a cartridge for transfer electrophoresis.  The cartridge was placed into a 
transfer electrophoresis box and filled with transfer buffer.  The transfer electrophoresis 
was then run, on ice, for 6 hours at 200 milliamps.  Ice was added throughout the 6 hour 
transfer as necessary to keep the transfer buffer from being heated.   
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Figure B.1. Arragnement of Cartridge for Transfer Electrophoresis. 
 
 
Blotting 
After the transfer had completed, the gels were discarded and the PVDF 
membrane was washed in TBST for 5 minutes on an orbital shaker set at 100rpm.  The 
TBST was discarded, and the PVDF membranes were blocked in a 5% milk solution 
(made with powdered milk and TBST) for 1 hour on an orbital shaker set at 100rpm.  
After the blocking step, the 5% milk was discarded.  The membranes were washed again, 
3 times for 5 minutes each, in TBST on an orbital shaker.  The TBST was discarded after 
each wash and new TBST was added.  Meanwhile, boxes for administration of primary 
antibodies were blocked for 15 minutes in 5% milk to reduce non-specific binding of the 
antibody to the plastic surface of the box.  The 5% milk was then discarded.  After 
washing, the membranes were placed in boxes on a rocker and 15ml of 5% milk with 
antibody was added. The membranes were then probed overnight with primary antibody 
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on the rocker at 4°C.  Primary antibodies for MCT1, 2, and 4 were purchased from Santa 
Cruz Biotechnologies (sc-50325, sc-50323, and sc-50329 for MCTs 1, 2, and 4 
respectively).  
When probing with the primary antibody was done, the 5% milk and antibody 
was discarded.  The membranes were washed again for 10 minutes in TBST.  The TBST 
was then discarded.  Then the membranes were washed 3 more times for 10 minutes each 
in 5% milk, discarding the used milk after each wash and adding fresh milk.  Meanwhile, 
the boxes for the administration of secondary antibodies were blocked for 30 minutes in 
5% milk.  The 5% milk was then discarded.  The membranes were then be put back into 
the boxes on the rocker.  Then 15 ml of 5% milk and antibody was added to each 
membrane.  The secondary antibody in 5% milk was put on the rocker at room 
temperature for 2 hours.  Once the secondary antibody was done incubating, the 
secondary antibody was discarded.  The membranes were then washed 4 times for 10 
minutes each in TBST, discarding used TBST with each wash.  The membranes were 
then soaked in ECL plus (PerkinElmer Inc. Waltham, Massachusetts) for 2 minutes and 
imaged on BioRad Chemidoc Station.  An example of these images for the MCTs can be 
seen in Figure B.2.  The band density was assessed using QuantityOne software on the 
same computer connected to the Chemidoc. 
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Figure B.2.  Example Blot of MCTs 4, 2, and 1 within the Hypothalamus. 
 
 
After the first exposure, the membranes were washed 2 times for 10 minutes each 
in stripping buffer to remove primary and secondary antibodies.  Used stripping buffer 
was discarded after each wash.  Once the stripping was completed, the membranes were 
washed 4 times for 10 minutes each in TBST, discarding used TBST each time.  The 
PVDF membranes were then blocked again in a 5% milk solution for 1 hour on an orbital 
shaker set at 100rpm.  The milk was then discarded.  After the blocking step, the 
membranes were washed again 3 times for 5 minutes each in TBST on an orbital shaker.  
Meanwhile, boxes for administration of primary antibodies were blocked for 15 minutes 
in 5% milk.  Used TBST and milk were then discarded.  After washing, the membranes 
were each placed in a box on a rocker and had primary antibodies delivered in 15ml of 
5% milk solution.  They were then probed overnight with the primary antibody at 4°C.  
The primary antibody for GAPDH (the loading control protein) was also purchased from 
Santa Cruz Biotechnologies (sc-166545). 
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When probing with the primary antibody was completed the antibody and milk 
solution was discarded, and the membranes were washed again for 10 minutes in TBST.  
The TBST was then discarded.  Then the membranes were washed 3 more times for 10 
minutes each in 5% milk.  Meanwhile, the boxes for the administration of secondary 
antibodies were blocked for 30 minutes in 5% milk.  The milk used for blocking or 
washing was then discarded.  The membranes were then put back on the rocker with 
15ml of 5% milk with secondary antibody.  They were then probed with secondary 
antibody at room temperature for 2 hours.  Once the secondary antibody was done 
incubating, the secondary antibody and milk solution was discarded.  The membranes 
were then washed 4 times for 10 minutes each in TBST.  The TBST was discarded after 
each wash.  The membranes were then soaked in ECL plus (PerkinElmer Inc. Waltham, 
Massachusetts) for 2 minutes and imaged on BioRad Chemidoc Station.  The band 
density were assessed using QuantityOne software on the same computer connected to 
the Chemidoc.  Finally, after this exposure, the membranes were discarded. 
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APPENDIX C 
 JUGULAR VEIN CATHETERIZATION PROTOCOL 
 
 
Preparation 
A jugular vein catheter was surgically implanted into some of the animals for 
multiple blood draws to assess changes in counter-regulatory hormones.  Before the 
surgery began, necessary tools, instruments, and the surgical area will be sterilized.  
Tools were sterilized using the autoclave before the surgery, or using a glass bead 
sterilizer between animals.  Immediately prior to the surgery, animals were injected with 
xylazine at a concentration of 1mg/ml and a dose of 1ml/kg body mass.  This relaxes the 
animal and makes it easier to further anesthetize.  After approximately 10 to 15 minutes, 
depending on the animal’s behavior, the animal was placed in an anesthetization chamber 
to deliver approximately 4% isoflurane (depending on rat size and behavior) at 400 ml of 
oxygen per minute.  Once the animal lost sternal recumbancy, it was moved from the 
chamber and fitted with a nose cone to continue to deliver isoflurane for the duration of 
the procedure; however the concentration was reduced to 2-3% depending on the size and 
needs of the animal.  The animal’s eyes were coated with ophthalmic lubricant to prevent 
them drying out during the procedure. 
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The animal’s head and chest were shaved using clippers, and a damp towel was 
used to remove any excess hair.  Once both sites were cleanly shaven, both sites were 
disinfected with 70% ethanol and povidone-iodine solutions, 3 times with each.  
Lidocaine was injected beneath the skin on top of the head, and allowed to absorb before 
the first incision was made.  Then the animal was completely wrapped within a sterile 
wrapping to protect the surgical site from any external contamination.  A hole was cut in 
the sterile wrappings above the head, and the chest to allow access to these areas during 
the surgery. 
Surgery 
First, a small incision along the mid-sagittal line was made on the top of the head 
to allow later access to the skull.  A piece of sterile gauze was applied to the top of the 
head to contain any bleeding as well as to prevent contamination of the incision.  The 
animal was then turned over to the supine position to expose the chest.  The skin was 
gently pinched and pulled away from the body where a small incision was made using 
surgical scissors.  The incision was then slowly spread by blunt dissection (repeatedly 
inserting closed scissors, and then gently spreading them).  This was done as opposed to 
cutting the flesh with the scissors (sharp dissection) to avoid damaging any organs or 
major blood vessels.  Once the jugular vein was revealed, it was carefully isolated using 
tweezers to slowly clean away fat and connective tissues.  When the jugular vein was 
cleanly isolated, a 20 gage needle was inserted into the vein as far anterior (cranial) to the 
animal as possible.  The needle was then be removed and a pair of sharp tweezers were 
inserted (closed) into the puncture hole.  These tweezers were gently spread to allow 
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space for the catheter to be inserted using a second set of blunt tweezers.  The catheter 
was then fed into the jugular vein until it was just above the right atrium.  If the catheter 
was unable to be moved forward, it was backed out slightly to avoid placing the tip in the 
right atrium.  Blood flow was checked using a 5ml syringe filled with saline to ensure 
that the tip of the catheter was not against a valve or vessel wall.  Two sutures were used 
to secure the catheter in place as well as prevent bleeding from the jugular vein.  Blood 
flow was checked using a 5ml syringe filled with saline to ensure that the sutures had not 
obstructed the flow.   
The animal was then be turned onto its side and its eyes were re-lubricated.  Using 
a cannula tunneling tool, the free end of the catheter was pushed through from the chest 
to the top of the skull.  The catheter was passed between the ear and eye of the animal, to 
exit through the incision initially made on the head.  Blood flow was then tested once 
more to ensure that the catheter is patent.  The incision on the chest was then closed using 
a surgical staple.  The animal was then be moved to the prone position with sterile gauze 
over the chest.  The connective tissue was scraped away from the skull using a scalpel 
blade, while being careful not to cut the catheter tubing.  Swabs were used to dry the area 
before drilling.  Then, three to four holes were drilled into the skull of the animal, taking 
care not to drill into the brain.  After drilling a hole, screws were inserted into the holes 
and screwed down about half way.  A space was left between the skull and the head of 
the screws to allow anchoring points for the dental epoxy.  Small pieces of gel foam 
clotting agent were placed under the skin along the sides of the work area to prevent any 
further bleeding or moisture entering the surgical area.  A dental epoxy was then be used 
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to secure the port end of the catheter between the heads of the screws, being sure to coat 
the entire area with epoxy, including beneath the heads of the screws. The catheter was 
held in place until the epoxy dried to ensure that the port is accessible, and at an angle 
that the rats cannot remove the stylet.  The catheter was then flushed and plugged with 
heparinized glycerol, and a stylet was used to cap the port.  Once this was done, the 
animal was removed from the isoflurane and unwrapped from the sterile wrappings.  The 
animal was then placed in a recovery cage which was placed on a heating pad.  The 
animal was monitored until it has recovered sternal recumbency and was observed 
grooming and eating (approximately 60 minutes).  The rat was then moved to a new tall 
cage, and is housed alone.  The tall cage ensured that the catheter port would not be 
accidently caught on the ceiling.  The animal would remain single housed in a tall cage 
for the remainder of the study. 
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APPENDIX D 
 BLOOD SAMPLE EXTRACTION PROCEDURE 
 
 
Equipment 
 Per Animal;  
  16” silicone tubing (marked with ruler) 
  1 plugged needle 
  Hemostat 
  Rinse/waste cup 
  Syringes 
   5 mL waste  
   5 mL saline 
   1 mL hep. saline with 25G needle 
   1 mL waste 
   0.25 mL donor blood “x” number of samples 
   1 mL for blood sample “x” number of samples 
  Vials “x” number of samples 
   1.5 mL vial prepared with 25ul hep. saline 
   0.6 mL vial labeled 
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General; 
   Mini-centrifuge  
   Pipet at 100ul and pipet tips 
   Ice box for samples 
Prior to Sampling 
15 minutes prior to sampling, prepare rats with 16” tube on catheters and rest over 
edge of the cage with hemostat.  Check plug for leaks before leaving unattended. 
   
Blood samples taken at -10min, 0min, 15min, 30min, 60min, 90min, and 120min 
(relative to injection time) to obtain a total of 7 samples.  First sample is taken 
~30 minutes after food was removed from the cage.  Total time for blood sample 
extraction is ~ 2.5 hours (150 minutes). 
Sampling for each time point, for each rat 
1. Clamp tubing with hemostat and remove plug 
2. Use 5 mL syringe (waste) to draw blood to the end of tubing 
3. Clamp with hemostat and remove waste syringe 
4. Connect sterilized collection syringe 
5. Draw 0.25 mL of blood with syringe held vertical 
6. Clamp hemostat and remove collection syringe 
7. Connect donor blood syringe  
8. Inject 0.25 mL of donor blood or saline if first run 
9. Clamp hemostat and remove donor syringe 
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10. Connect hep saline syringe and add small amount with fine needle at tube 
opening 
11. Flick the end of tubing to create a small bubble in the tube 
12. Clamp hemostat and remove hep saline syringe 
13. Connect saline syringe and push bubble 3” down tube 
14. Clamp hemostat and remove saline syringe  
15. Flick the end of tubing to create a small bubble 
16. Connect saline syringe again and push through the tube until 2nd bubble is at 
the top of rats metal catheter piece 
17. Clamp and cap until next sample run time in ~30 minutes 
Processing Each Sample 
1. Gently introduce 0.25 mL sample into large vial prepped with 25ul of hep 
saline (hep saline should be 1/10th the amount of sample added) 
Centrifuge until plasma is separated (~1-2 minutes) 
2. Pipet plasma and add to properly labeled vial  
3. Store plasma vial in ice box 
4. Add ~100ul of sterile saline to remaining sample and draw into a 1.0 mL 
syringe 
a. This will become the donor blood for the next sampling 
procedure 
  Total sample time: Approximately 6 minutes 
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APPENDIX E 
 PLASMA CATECHOLAMINE EXTRACTION 
 
 
Supplies 
a) Costar Spin-X micro centrifuge filter tubes with 0.2 m nylon filter. 
(Corning Inc., catalog nr. 8169), (Fischer # 07-200-389) 
b) 2 mL flat cap microcentrifuge tubes (USA Scientific Inc, # 1620-2799) 
c) Acid washed aluminum oxide (BAS # CF-8010) 
d) 0.2 N HClO4 
e) CE Tris Base (Fischer # BP152-500) 
f) DHBA solution for internal standard 
g) Brass Poederschepje scoop (patent pending) for dosing alumina 
h) Multivortex 
i) Centrifuge 
Procedure 
1. Label 24 (max) centrifuge filter tubes, the corresponding microcentrifuge 
tubes, and the corresponding autosampler vials. It is important to keep a 
record (on paper) where your samples go! 
2. Weigh out 10 mg aluminum oxide into the filter tubes using the brass 
scoop. 
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3. Add 500 L CE Tris buffer to each filter tube, make sure that the CE Tris 
buffer is at room temperature.  
4. Pipette 80 L DHBA standard (20 pg/20 L) into each filter tube.  
5. Pipette 100 L plasma into each filter tube. Write down the exact sample 
volume when there is less than 100 L available. Use a new yellow tip for 
each sample. Cap the tubes and vortex immediately (catecholamines are 
unstable at pH 8.6!) on the multivortex for 10 min. Make sure you observe 
the alumina dispersed within the tubes. 
6. Centrifuge the tubes for 3 min at 12000 rpm and 4 C. 
7. With each tube: Drain the filtrate, reassemble the tube, and add ~500 L 
deionized water from the dispenser. 
8. Centrifuge again for 1 min At 12000 rpm and 4 C. But extend the time as 
necessary for all of the water to clear the filter. 
9. Repeat the wash procedure (steps 7 & 8) three more times. 
10. Drain filtrate and centrifuge for 2 min at 12000 rpm to dry out the 
alumina. 
11. With each tube: Transfer the filter assembly (top part) onto the new 
microcentrifuge tube with its corresponding label. 
12. Pipette 80 L HClO4 0.2 N into the filter tubes, and vortex briefly on the 
multivortex. Turn off the vortex and let the tubes incubate for 5 min. 
13. Centrifuge the tubes for 2 min at 12000 rpm and 4 C. 
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14. Transfer the filtrate to the labeled autosampler vials and cap. Should be 80 
µl. Refrigerate when not used immediately! 
Remember to Include 
1. vial of the DHBA internal standard used. 
2. vial of the acid used. 
3. vial of Aluminum + DHBA 
4. vial of Aluminum. 
 
 
 
 
 
 
 
 
 
 
